https://trial.medpath.com/news/schizophrenia-clinical-trial-pipeline-insights-featuring-55-companies-delveinsight 2024-10-09T17:03:15+00:00 weekly 0.7 https://trial.medpath.com/news/study-reveals-potential-to-improve-car-t-therapy-efficiency-using-graphene-oxide 2024-10-09T16:57:59+00:00 weekly 0.7 https://trial.medpath.com/news/allurion-s-swallowable-balloon-hits-trial-success-amid-weakening-financials 2024-10-09T16:21:59+00:00 weekly 0.7 https://trial.medpath.com/news/phaxiam-therapeutics-announces-the-validation-of-a-new-investigator-initiated-phase-2-study 2024-10-09T16:15:04+00:00 weekly 0.7 https://trial.medpath.com/news/gene-expression-test-may-predict-added-atezolizumab-benefit-in-tnbc-cancer-network 2024-10-09T16:03:54+00:00 weekly 0.7 https://trial.medpath.com/news/springbok-analytics-receives-fda-510-k-clearance-for-muscleviewtm-its-ai-muscle 2024-10-09T16:00:43+00:00 weekly 0.7 https://trial.medpath.com/news/fast-track-designation-granted-to-liafensine-for-treatment-resistant-depression 2024-10-09T15:49:39+00:00 weekly 0.7 https://trial.medpath.com/news/multidisciplinary-approach-to-treatment-emerging-techniques-optimize-survival-and 2024-10-09T15:47:50+00:00 weekly 0.7 https://trial.medpath.com/news/lbl-024-receives-breakthrough-therapy-designation-in-china-for-extrapulmonary-onclive 2024-10-09T15:46:22+00:00 weekly 0.7 https://trial.medpath.com/news/delivering-on-the-promise-of-living-drugs-roswell-park-comprehensive-cancer-center 2024-10-09T15:32:29+00:00 weekly 0.7 https://trial.medpath.com/news/assessment-of-fda-premarket-approval-process-and-suggestions-for-improvement-jama-network 2024-10-09T15:29:55+00:00 weekly 0.7 https://trial.medpath.com/news/q-a-amy-mcmichael-md-discusses-48-week-visible-study-results-on-psoriasis-in 2024-10-09T15:22:34+00:00 weekly 0.7 https://trial.medpath.com/news/envafolimab-plus-lenvatinib-and-transcatheter-arterial-chemoembolization-for-unresectable 2024-10-09T15:08:05+00:00 weekly 0.7 https://trial.medpath.com/news/largest-whole-exome-sequencing-study-of-epilepsy-to-date-finds-new-genetic-links 2024-10-09T15:01:09+00:00 weekly 0.7 https://trial.medpath.com/news/uw-health-eastpark-medical-center-integrates-clinical-trials-into-patient-care-wispolitics 2024-10-09T14:51:17+00:00 weekly 0.7 https://trial.medpath.com/news/calluna-pharma-names-ceo 2024-10-09T14:37:17+00:00 weekly 0.7 https://trial.medpath.com/news/viking-therapeutics-reveals-encouraging-data-from-genetic-disorder-drug-study-analyst 2024-10-09T14:13:27+00:00 weekly 0.7 https://trial.medpath.com/news/philly-biotech-to-deliver-first-of-its-kind-cancer-therapy-the-philadelphia-inquirer 2024-10-09T14:09:24+00:00 weekly 0.7 https://trial.medpath.com/news/mifepristone-maker-to-seek-fda-ok-for-use-of-drug-to-treat-miscarriages 2024-10-09T13:58:04+00:00 weekly 0.7 https://trial.medpath.com/news/parkinson-s-discovery-suggests-we-already-have-an-fda-approved-treatment 2024-10-09T13:41:03+00:00 weekly 0.7 https://trial.medpath.com/news/kymera-therapeutics-announces-fda-clearance-of-investigational-new-drug-application 2024-10-09T13:40:17+00:00 weekly 0.7 https://trial.medpath.com/news/longeveron-r-lomecel-btm-5-year-long-term-transplant-free-survival-data-in-hlhs-biospace 2024-10-09T13:40:17+00:00 weekly 0.7 https://trial.medpath.com/news/recce-pharmaceuticals-reaches-midpoint-in-phase-ii-trial-for-topical-gel-r327g 2024-10-09T13:14:46+00:00 weekly 0.7 https://trial.medpath.com/news/ai-squared-awarded-1-5m-phase-iii-small-business-innovative-research-contract-with 2024-10-09T13:07:21+00:00 weekly 0.7 https://trial.medpath.com/news/can-sure-shot-reduce-the-effects-of-alcohol-clinical-studies-look-promising-forbes 2024-10-09T13:04:41+00:00 weekly 0.7 https://trial.medpath.com/news/alabama-unveils-program-to-expand-free-genetic-testing-clinical-trial-participation 2024-10-09T12:59:49+00:00 weekly 0.7 https://trial.medpath.com/news/nitches-inc-launches-new-vertical-with-american-made-bioceutical-company-introducing 2024-10-09T12:34:51+00:00 weekly 0.7 https://trial.medpath.com/news/biogen-felzartamab-receives-breakthrough-therapy-designation-quick-facts-rttnews 2024-10-09T12:31:28+00:00 weekly 0.7 https://trial.medpath.com/news/novos-glp-1-wegovy-could-improve-heart-health-for-millions-more-than-previously 2024-10-09T12:21:43+00:00 weekly 0.7 https://trial.medpath.com/news/risk-and-benefit-of-restrictive-transfusion-strategies-in-neurocritically-ill-patients 2024-10-09T12:20:39+00:00 weekly 0.7 https://trial.medpath.com/news/frequency-of-screening-and-spontaneous-breathing-trial-techniques-a-randomized-clinical-trial 2024-10-09T12:20:30+00:00 weekly 0.7 https://trial.medpath.com/news/evaluating-complex-technological-innovations-in-critical-care-jama-network 2024-10-09T12:20:28+00:00 weekly 0.7 https://trial.medpath.com/news/stealth-s-ultrarare-disease-candidate-might-not-meet-bar-for-approval-fda-biospace 2024-10-09T12:11:44+00:00 weekly 0.7 https://trial.medpath.com/news/viatris-announces-positive-top-line-results-from-phase-3-study-of-effexor-r-in-japanese 2024-10-09T12:08:38+00:00 weekly 0.7 https://trial.medpath.com/news/innocare-announces-phase-ii-study-results-of-tyk2-inhibitor-icp-488-meet-primary 2024-10-09T12:05:26+00:00 weekly 0.7 https://trial.medpath.com/news/cisplatin-shortage-in-2023-forces-treatment-changes-and-drives-up-costs-in-head-and-neck-cancer-care 2024-10-09T11:52:15+00:00 weekly 0.7 https://trial.medpath.com/news/new-data-to-be-presented-at-idweek-2024-reinforce-merck-s-broad-and-diverse-vaccines 2024-10-09T11:25:04+00:00 weekly 0.7 https://trial.medpath.com/news/ocugen-inc-announces-removal-of-clinical-hold-on-investigational-new-drug-application 2024-10-09T11:23:09+00:00 weekly 0.7 https://trial.medpath.com/news/scaleready-announces-a-g-rex-r-grant-has-been-awarded-to-lift-biosciences 2024-10-09T11:16:42+00:00 weekly 0.7 https://trial.medpath.com/news/novavax-s-updated-2024-2025-nuvaxovidtm-covid-19-vaccine-receives-authorization-in-the-eu 2024-10-09T11:16:40+00:00 weekly 0.7 https://trial.medpath.com/news/jak-inhibitor-combinations-and-cellular-therapy-shape-future-directions-in-myelofibrosis-treatment 2024-10-09T11:15:05+00:00 weekly 0.7 https://trial.medpath.com/news/gamification-shows-promise-in-boosting-clinical-trial-patient-retention-and-engagement 2024-10-09T11:03:50+00:00 weekly 0.7 https://trial.medpath.com/news/the-latest-updates-from-the-gene-editing-clinical-trials-october-2024 2024-10-09T11:02:27+00:00 weekly 0.7 https://trial.medpath.com/news/clearside-biomedical-unveils-positive-topline-results-from-odyssey-phase-2b-trial-of 2024-10-09T10:40:04+00:00 weekly 0.7 https://trial.medpath.com/news/indonesia-supports-atmp-research-expands-clinical-trials-antara-news 2024-10-09T10:11:18+00:00 weekly 0.7 https://trial.medpath.com/news/buy-rating-for-enanta-pharmaceuticals-amid-reduced-competition-and-promising-drug-trials 2024-10-09T09:33:38+00:00 weekly 0.7 https://trial.medpath.com/news/regenerative-bioscience-s-meniscus-implant-receives-fda-clearance 2024-10-09T09:22:51+00:00 weekly 0.7 https://trial.medpath.com/news/q-a-how-the-fda-is-approaching-ai-in-clinical-trials-and-drug-development 2024-10-09T08:38:09+00:00 weekly 0.7 https://trial.medpath.com/news/duke-nus-duo-create-precision-tool-for-liver-cancer-mirage-news 2024-10-09T08:36:31+00:00 weekly 0.7 https://trial.medpath.com/news/response-based-intermittent-ibrutinib-dosing-shows-safety-feasibility-in-cll-onclive 2024-10-09T08:08:09+00:00 weekly 0.7 https://trial.medpath.com/news/tevogen-bio-highlights-promising-trial-data-as-ceo-leads-patient-advocacy-at-capitol-hill 2024-10-09T08:04:28+00:00 weekly 0.7 https://trial.medpath.com/news/kineta-announces-completion-of-enrollment-in-the-monotherapy-arm-of-the-vista-101-biospace 2024-10-09T07:07:07+00:00 weekly 0.7 https://trial.medpath.com/news/genetic-study-reveals-one-way-link-between-cardiovascular-disease-and-psoriasis-risk 2024-10-09T07:00:57+00:00 weekly 0.7 https://trial.medpath.com/news/fast-news-cspc-pharma-s-urticaria-drug-approved-in-china-bamboo-works 2024-10-09T05:54:29+00:00 weekly 0.7 https://trial.medpath.com/news/the-impact-of-fu-s-subcutaneous-needling-on-lower-limb-muscle-stiffnes-jpr 2024-10-09T05:18:42+00:00 weekly 0.7 https://trial.medpath.com/news/closed-loop-medicine-pioneers-precision-medicine-through-drug-software-integration 2024-10-09T05:01:00+00:00 weekly 0.7 https://trial.medpath.com/news/novel-epigenetic-liquid-biopsy-platform-shows-promise-in-detecting-psma-expression-for-prostate-cancer-treatment 2024-10-09T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sexual-health-and-quality-of-life-with-simple-vs-radical-hysterectomy-in-low-risk-early 2024-10-09T04:53:54+00:00 weekly 0.7 https://trial.medpath.com/news/personalized-medicine-emerges-as-key-to-future-multiple-myeloma-treatment-success 2024-10-09T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/stealth-s-elamipretide-efficacy-in-barth-syndrome-not-shown-us-fda-says-pink-sheet 2024-10-09T03:25:08+00:00 weekly 0.7 https://trial.medpath.com/news/recce-pharmaceuticals-progresses-phase-2-trial-for-bacterial-skin-infections-passing 2024-10-09T03:06:55+00:00 weekly 0.7 https://trial.medpath.com/news/dermata-therapeutics-to-participate-in-the-2024-maxim-healthcare-virtual-summit-on-quantisnow 2024-10-09T02:33:08+00:00 weekly 0.7 https://trial.medpath.com/news/clarity-enters-a-clinical-manufacturing-agreement-for-cu-64-sar-bispsma-with-spectronrx 2024-10-09T02:31:27+00:00 weekly 0.7 https://trial.medpath.com/news/sage-nmda-modulator-fails-in-alzheimer-s-months-after-parkinson-s-disappointment-scrip 2024-10-09T02:00:13+00:00 weekly 0.7 https://trial.medpath.com/news/danco-laboratories-to-seek-fda-approval-for-mifepristone-in-miscarriage-management 2024-10-09T01:28:31+00:00 weekly 0.7 https://trial.medpath.com/news/recon-gsk-pfizer-rsv-vaccine-sales-drop-in-the-us-sage-abandons-alzheimer-s-drug 2024-10-09T01:12:14+00:00 weekly 0.7 https://trial.medpath.com/news/globus-medical-in-2024-6-notes 2024-10-09T00:48:35+00:00 weekly 0.7 https://trial.medpath.com/news/fda-issues-second-crl-for-dasiglucagon-to-treat-hypoglycemia-in-congenital-hyperinsulinism 2024-10-09T00:11:28+00:00 weekly 0.7 https://trial.medpath.com/news/innovative-clinical-trial-designs-for-assessing-treatment-effects-on-kidney-function 2024-10-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/why-soleno-therapeutics-stock-blasted-9-higher-today-the-globe-and-mail 2024-10-08T23:27:40+00:00 weekly 0.7 https://trial.medpath.com/news/5-year-outcomes-add-supportive-evidence-to-approved-gene-therapy-for-duchenne 2024-10-08T22:52:16+00:00 weekly 0.7 https://trial.medpath.com/news/basecamp-research-secures-60m-and-partners-with-broad-institute-to-advance-ai-driven-genetic-medicine 2024-10-08T22:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-ad-comm-to-consider-rare-disease-treatment-amid-advocacy-push-fda-efficacy-concerns 2024-10-08T21:14:50+00:00 weekly 0.7 https://trial.medpath.com/news/pulmonology-month-in-review-september-2024-hcplive 2024-10-08T21:03:25+00:00 weekly 0.7 https://trial.medpath.com/news/lab-data-analytics-revolutionizes-patient-identification-and-treatment-targeting-in-pharma-industry 2024-10-08T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4c-medical-commences-enrollment-in-heart-valve-trial-massdevice 2024-10-08T20:47:47+00:00 weekly 0.7 https://trial.medpath.com/news/new-subgroup-analyses-from-landmark-phase-3-aspen-study-of-brensocatib-in-patients 2024-10-08T20:38:40+00:00 weekly 0.7 https://trial.medpath.com/news/aviadobio-and-astellas-ink-potential-2-5b-deal-for-frontotemporal-dementia-candidate 2024-10-08T20:37:17+00:00 weekly 0.7 https://trial.medpath.com/news/former-columbia-university-psychiatrist-committed-research-misconduct-says-federal-watchdog 2024-10-08T19:15:00+00:00 weekly 0.7 https://trial.medpath.com/news/vici-health-sciences-announces-launch-of-phase-i-phase-ii-and-phase-iii-clinical-supplies 2024-10-08T18:58:50+00:00 weekly 0.7 https://trial.medpath.com/news/fourth-non-browning-apple-made-in-summerland-gets-fda-approval-vancouver-sun 2024-10-08T18:58:40+00:00 weekly 0.7 https://trial.medpath.com/news/mindbio-develops-long-term-shelf-stable-microdosing-formulation-and-is-progressing-in 2024-10-08T18:14:01+00:00 weekly 0.7 https://trial.medpath.com/news/lifesciences-and-healthcare-newsletter-august-2024-life-sciences-biotechnology 2024-10-08T18:13:06+00:00 weekly 0.7 https://trial.medpath.com/news/adc-and-cdk4-6-inhibitor-decision-making-and-sequencing-questions-abound-in-breast-cancer 2024-10-08T18:08:06+00:00 weekly 0.7 https://trial.medpath.com/news/sage-continues-downslide-as-alzheimer-s-study-fails-biopharma-dive 2024-10-08T17:21:28+00:00 weekly 0.7 https://trial.medpath.com/news/french-agency-places-novo-nordisk-s-anti-obesity-drug-under-close-surveillance-euractiv 2024-10-08T16:22:48+00:00 weekly 0.7 https://trial.medpath.com/news/humacyte-late-breaking-abstract-accepted-for-oral-presentation-on-v007-phase-3-av-biospace 2024-10-08T16:15:11+00:00 weekly 0.7 https://trial.medpath.com/news/startup-led-by-john-maraganore-raises-135m-to-build-future-of-rnai-biopharma-dive 2024-10-08T16:06:12+00:00 weekly 0.7 https://trial.medpath.com/news/srrk-stock-soars-as-muscle-disease-drug-meets-phase-iii-study-goal-barchart-com 2024-10-08T16:05:20+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-breakthrough-device-designation-to-ai-powered-aortic-stenosis-screening-tool 2024-10-08T15:38:26+00:00 weekly 0.7 https://trial.medpath.com/news/gastrointestinal-medical-oncologist-and-researcher-driven-to-help-patients-live-longer 2024-10-08T15:08:23+00:00 weekly 0.7 https://trial.medpath.com/news/dr-reddy-s-unit-achieves-trial-breakthrough-positive-results-for-blood-cancer-treatment 2024-10-08T14:26:18+00:00 weekly 0.7 https://trial.medpath.com/news/parp1-selective-inhibitors-generate-excitement-in-solid-tumors-onclive 2024-10-08T14:21:20+00:00 weekly 0.7 https://trial.medpath.com/news/who-updates-cervical-cancer-prevention-guidelines-oncology-nursing-news 2024-10-08T14:03:13+00:00 weekly 0.7 https://trial.medpath.com/news/interpreting-modern-randomized-controlled-trials-of-medical-therapy-in-inflammatory-bowel-disease 2024-10-08T13:57:12+00:00 weekly 0.7 https://trial.medpath.com/news/adcendo-announces-us-fda-clearance-of-ind-application-for-phase-i-ii-first-in-human 2024-10-08T13:30:43+00:00 weekly 0.7 https://trial.medpath.com/news/pharmala-to-supply-the-university-of-texas-san-antonio-with-novel-dosage-form-of-laneotm-mdma 2024-10-08T13:15:11+00:00 weekly 0.7 https://trial.medpath.com/news/oragenics-inc-successfully-completes-key-fda-recognized-study-for-onp-002 2024-10-08T13:12:09+00:00 weekly 0.7 https://trial.medpath.com/news/biosimilar-rituximab-safe-effective-for-sle-after-switching 2024-10-08T13:09:33+00:00 weekly 0.7 https://trial.medpath.com/news/all-the-news-that-s-fit-alzheimer-s-drug-study-rice-balls-record-and-hawking-s-words 2024-10-08T12:44:06+00:00 weekly 0.7 https://trial.medpath.com/news/pierre-fabre-laboratories-and-scorpion-therapeutics-announce-first-patient-dosed-in 2024-10-08T12:38:05+00:00 weekly 0.7 https://trial.medpath.com/news/teva-pharma-fda-to-review-bla-for-tvb-009p-quick-facts-markets-insider 2024-10-08T12:37:46+00:00 weekly 0.7 https://trial.medpath.com/news/avalo-announces-first-patient-dosed-in-phase-2-lotus-trial-of-avtx-009-for-the-treatment 2024-10-08T12:36:26+00:00 weekly 0.7 https://trial.medpath.com/news/sage-therapeutics-announces-topline-results-from-the-phase-2-lightwave-study-of-biospace 2024-10-08T12:36:07+00:00 weekly 0.7 https://trial.medpath.com/news/rgenta-therapeutics-announces-first-patients-dosed-in-phase-1a-b-clinical-trial-of-rgt 2024-10-08T12:15:56+00:00 weekly 0.7 https://trial.medpath.com/news/nkgen-biotech-announces-poster-presentations-at-the-17th-globenewswire 2024-10-08T12:10:33+00:00 weekly 0.7 https://trial.medpath.com/news/verismo-therapeutics-announces-the-activation-of-its-celestial-301-clinical-trial-at 2024-10-08T12:05:32+00:00 weekly 0.7 https://trial.medpath.com/news/avextra-announces-the-approval-of-neurobis-by-the-italian-globenewswire 2024-10-08T11:12:59+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-discontinues-phase-iii-study-of-treatment-for-bladder-cancer 2024-10-08T10:42:17+00:00 weekly 0.7 https://trial.medpath.com/news/sustained-effect-of-prasinezumab-on-parkinson-s-disease-motor-progression-in-the-open-nature 2024-10-08T10:25:30+00:00 weekly 0.7 https://trial.medpath.com/news/eu-notified-body-bsi-netherlands-and-the-ema-grant-approval-of-the-leukostrat-r-cdx 2024-10-08T10:24:29+00:00 weekly 0.7 https://trial.medpath.com/news/could-music-lessons-help-clear-the-brain-fog-of-chemotherapy 2024-10-08T10:10:45+00:00 weekly 0.7 https://trial.medpath.com/news/kyowa-kirin-announces-positive-interim-real-world-data-for-mogamulizumab-poteligeo 2024-10-08T10:02:36+00:00 weekly 0.7 https://trial.medpath.com/news/ai-enabled-remote-cardiac-monitoring-reveals-critical-link-between-sleep-and-heart-health 2024-10-08T10:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/scholar-rock-heading-to-finish-line-in-sma-with-positive-pivotal-data-scrip-citeline 2024-10-08T09:49:51+00:00 weekly 0.7 https://trial.medpath.com/news/fish-skin-grafts-outperform-current-treatments-in-diabetic-foot-ulcers-clinical-trials-arena 2024-10-08T09:47:35+00:00 weekly 0.7 https://trial.medpath.com/news/nch-health-rooney-heart-institute-announces-successful-clinical-trial 2024-10-08T09:31:26+00:00 weekly 0.7 https://trial.medpath.com/news/consideration-of-factors-of-low-accrual-and-methods-for-setting-appropriate-accrual-periods 2024-10-08T08:29:01+00:00 weekly 0.7 https://trial.medpath.com/news/survey-reveals-strong-allergist-support-for-biologics-in-food-allergy-treatment-despite-cost-concerns 2024-10-08T08:07:21+00:00 weekly 0.7 https://trial.medpath.com/news/zealand-pharma-announces-that-boehringer-receives-u-s-fda-breakthrough-therapy 2024-10-08T06:46:21+00:00 weekly 0.7 https://trial.medpath.com/news/apitegromab-shows-promise-in-phase-iii-spinal-muscular-atrophy-trial-scholar-rock-reports 2024-10-08T06:17:01+00:00 weekly 0.7 https://trial.medpath.com/news/kronos-bio-announces-selection-of-autoimmune-development-candidate-for-sjogren-s-disease 2024-10-08T05:39:53+00:00 weekly 0.7 https://trial.medpath.com/news/sk-biopharm-and-eurofarma-submit-nda-for-epilepsy-drug-in-brazil-businesskorea 2024-10-08T05:16:59+00:00 weekly 0.7 https://trial.medpath.com/news/cybrexa-therapeutics-announces-first-patient-dosed-with-first-in-class-peptide-drug-biospace 2024-10-08T05:12:30+00:00 weekly 0.7 https://trial.medpath.com/news/alzamend-neuro-partners-with-massachusetts-general-hospital-for-a-phase-ii-clinical-trial 2024-10-08T04:35:53+00:00 weekly 0.7 https://trial.medpath.com/news/glytherix-and-eckert-ziegler-sign-agreement-for-lutetium-177-supply 2024-10-08T02:38:09+00:00 weekly 0.7 https://trial.medpath.com/news/ptc-therapeutics-announces-positive-results-from-long-term-treatment-studies-and-updates-on-regulatory-progress-for-vatiquinone-friedreich-ataxia-program 2024-10-08T02:10:13+00:00 weekly 0.7 https://trial.medpath.com/news/inspire-trial-investigates-immunotherapy-for-molecularly-selected-advanced-prostate-cancer 2024-10-08T01:09:05+00:00 weekly 0.7 https://trial.medpath.com/news/orthocell-garners-regulatory-approval-for-remplir-in-gateway-asian-market-of-singapore 2024-10-08T00:57:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-authorizes-marketing-of-first-home-flu-and-covid-19-combination-test-outside-of 2024-10-08T00:19:40+00:00 weekly 0.7 https://trial.medpath.com/news/stereotactic-ablative-radiotherapy-shows-promise-in-pancreatic-cancer-treatment-while-phase-3-trial-questions-chemoradiation-benefits 2024-10-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/study-shows-ai-helps-boost-breast-screening-accuracy 2024-10-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ascentage-pharma-s-apg-2449-advances-to-phase-iii-tipranks-com 2024-10-07T23:49:51+00:00 weekly 0.7 https://trial.medpath.com/news/insignis-therapeutics-announces-positive-results-from-phase-1-clinical-study-of-in-001 2024-10-07T22:46:35+00:00 weekly 0.7 https://trial.medpath.com/news/tci-unveils-promising-glp-1-formula-clinical-trial-results-for-advanced-weight-management 2024-10-07T22:10:45+00:00 weekly 0.7 https://trial.medpath.com/news/scholar-rock-drug-for-spinal-muscular-atrophy-succeeds-in-late-stage-study-stat-news 2024-10-07T21:49:47+00:00 weekly 0.7 https://trial.medpath.com/news/elanco-receives-fda-approval-for-credelio-quattrotm-lotilaner-moxidectin-praziquantel 2024-10-07T20:22:17+00:00 weekly 0.7 https://trial.medpath.com/news/procept-biorobotics-received-u-s-fda-approval-to-initiate-globenewswire 2024-10-07T20:10:11+00:00 weekly 0.7 https://trial.medpath.com/news/nurses-are-critical-partners-in-the-clinical-trial-process-oncology-nursing-news 2024-10-07T19:11:55+00:00 weekly 0.7 https://trial.medpath.com/news/recruitment-of-emergency-department-patients-to-a-prospective-observational-study 2024-10-07T18:39:09+00:00 weekly 0.7 https://trial.medpath.com/news/biodefense-headlines-7-october-2024 2024-10-07T18:35:44+00:00 weekly 0.7 https://trial.medpath.com/news/neuvivo-seeks-fda-approval-for-its-breakthrough-als-treatment-np001 2024-10-07T18:10:21+00:00 weekly 0.7 https://trial.medpath.com/news/gotistobart-plus-pembrolizumab-shows-activity-in-platinum-resistant-ovarian-cancer 2024-10-07T18:01:40+00:00 weekly 0.7 https://trial.medpath.com/news/study-shows-cancer-vaccine-blocks-tumor-progression-at-early-lesion-stage-vumc-news 2024-10-07T17:51:19+00:00 weekly 0.7 https://trial.medpath.com/news/the-biotech-news-stories-you-need-to-read-this-morning 2024-10-07T17:31:13+00:00 weekly 0.7 https://trial.medpath.com/news/substantial-delays-in-postapproval-pediatric-testing-for-new-drugs 2024-10-07T16:43:55+00:00 weekly 0.7 https://trial.medpath.com/news/therapeutic-antibodies-against-the-marburg-virus-tu-braunschweig-blogs 2024-10-07T16:43:10+00:00 weekly 0.7 https://trial.medpath.com/news/having-trouble-quitting-vaping-you-re-not-the-only-one-time 2024-10-07T16:25:00+00:00 weekly 0.7 https://trial.medpath.com/news/2-minute-medicine-rewind-october-7-2024 2024-10-07T16:15:24+00:00 weekly 0.7 https://trial.medpath.com/news/bringing-research-to-patients-home-to-improve-quality-of-life-in-palliative-care-nihr 2024-10-07T16:15:05+00:00 weekly 0.7 https://trial.medpath.com/news/fda-taps-urmc-to-develop-new-digital-measures-for-huntington-s-disease 2024-10-07T16:09:02+00:00 weekly 0.7 https://trial.medpath.com/news/gbi-biomanufacturing-and-allterum-therapeutics-announce-strategic-collaboration-to 2024-10-07T16:05:00+00:00 weekly 0.7 https://trial.medpath.com/news/trial-of-kezar-s-only-active-drug-halted-after-five-patients-die-scrip-citeline 2024-10-07T16:01:37+00:00 weekly 0.7 https://trial.medpath.com/news/evaluating-tools-for-assessing-bias-in-a-meta-analysis-of-clinical-trials-on-race-and-ras 2024-10-07T15:45:05+00:00 weekly 0.7 https://trial.medpath.com/news/indivior-s-sublocade-r-rapid-induction-alternative-injection-site-prior-approval-pr-newswire 2024-10-07T15:32:50+00:00 weekly 0.7 https://trial.medpath.com/news/circulating-tumor-cell-count-and-overall-survival-in-patients-with-metastatic-hormone 2024-10-07T15:30:06+00:00 weekly 0.7 https://trial.medpath.com/news/cancer-biologists-discover-a-new-mechanism-for-an-old-drug-mit-news 2024-10-07T15:28:22+00:00 weekly 0.7 https://trial.medpath.com/news/testing-of-new-drugs-approved-from-2015-to-2021-under-the-us-pediatric-research-equity-act 2024-10-07T15:11:14+00:00 weekly 0.7 https://trial.medpath.com/news/evaluating-tools-for-assessing-bias-in-a-meta-analysis-of-clinical-trials-on-race-and-ras-blockade 2024-10-07T15:11:11+00:00 weekly 0.7 https://trial.medpath.com/news/are-people-holding-their-arms-incorrectly-for-blood-pressure-tests 2024-10-07T15:10:32+00:00 weekly 0.7 https://trial.medpath.com/news/early-blood-test-can-predict-survival-in-men-newly-diagnosed-with-metastatic-prostate-cancer 2024-10-07T15:08:30+00:00 weekly 0.7 https://trial.medpath.com/news/cytodyn-announces-abstract-that-highlights-leronlimab-s-potential-in-mediating-art-free 2024-10-07T15:06:34+00:00 weekly 0.7 https://trial.medpath.com/news/us-scientists-win-nobel-prize-for-gene-regulation-breakthrough-punch-newspapers 2024-10-07T14:56:09+00:00 weekly 0.7 https://trial.medpath.com/news/protac-protein-degraders-to-drug-the-undruggable-enter-phase-3-trials-nature 2024-10-07T14:31:42+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-3-tubes-of-aminolevulinic-acid-hydrochloride-for-actinic-keratosis-hcplive 2024-10-07T14:29:46+00:00 weekly 0.7 https://trial.medpath.com/news/senex-biotechnology-receives-notice-of-allowance-for-novel-cdk8-19-inhibitors-from-benzinga 2024-10-07T14:24:28+00:00 weekly 0.7 https://trial.medpath.com/news/results-and-outcome-of-the-aegean-trial-targeted-oncology 2024-10-07T14:21:40+00:00 weekly 0.7 https://trial.medpath.com/news/united-states-supreme-court-declines-to-review-rulings-that-invalidate-united-therapeutics-patent 2024-10-07T14:05:28+00:00 weekly 0.7 https://trial.medpath.com/news/alk-abello-announces-fda-approval-of-accutest-allergy-skin-testing-devices-tipranks 2024-10-07T13:44:27+00:00 weekly 0.7 https://trial.medpath.com/news/the-nimml-institute-and-nimmune-biopharma-announce-publication-of-new-mechanistic 2024-10-07T13:43:44+00:00 weekly 0.7 https://trial.medpath.com/news/new-government-tech-deals-boost-the-business-of-cancer-detection-wired-gov 2024-10-07T13:35:36+00:00 weekly 0.7 https://trial.medpath.com/news/continuous-lateral-rotation-therapy-in-mv-does-not-affect-mortality-los 2024-10-07T13:31:29+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-status-to-ultragenyx-s-osteogenesis-imperfecta-drug 2024-10-07T13:21:38+00:00 weekly 0.7 https://trial.medpath.com/news/scholar-rock-s-phase-3-sapphire-study-of-apitegromab-in-sma-meets-primary-goal-stock-surges 2024-10-07T13:14:38+00:00 weekly 0.7 https://trial.medpath.com/news/neuvivo-seeks-fda-approval-for-its-breakthrough-als-treatment-np001-yahoo-finance 2024-10-07T13:08:28+00:00 weekly 0.7 https://trial.medpath.com/news/largest-lung-cancer-clinical-trial-starts-to-recruit-patients-at-the-christie 2024-10-07T13:08:16+00:00 weekly 0.7 https://trial.medpath.com/news/biomea-fusion-to-present-at-the-1st-annual-asian-conference-globenewswire 2024-10-07T13:06:22+00:00 weekly 0.7 https://trial.medpath.com/news/anixa-biosciences-appoints-suyasha-gupta-as-senior-director-of-clinical-development 2024-10-07T12:54:54+00:00 weekly 0.7 https://trial.medpath.com/news/fluoguide-submits-clinical-trial-application-for-head-and-neck-cancer-treatment 2024-10-07T12:43:46+00:00 weekly 0.7 https://trial.medpath.com/news/rege-nephro-co-ltd-successfully-completes-series-b-funding-to-accelerate-kidney 2024-10-07T12:36:14+00:00 weekly 0.7 https://trial.medpath.com/news/trinity-biotech-announces-positive-pre-pivotal-trial-results-for-its-next-generation 2024-10-07T12:34:49+00:00 weekly 0.7 https://trial.medpath.com/news/design-and-rationale-for-an-empirical-investigation-of-the-resource-use-and-costs-of-trials-journal 2024-10-07T12:25:48+00:00 weekly 0.7 https://trial.medpath.com/news/bias-found-when-drug-manufacturers-fund-clinical-trials-ohio-state-news 2024-10-07T12:16:31+00:00 weekly 0.7 https://trial.medpath.com/news/bioatla-to-score-up-to-133m-san-diego-business-journal 2024-10-07T12:12:41+00:00 weekly 0.7 https://trial.medpath.com/news/monopar-initiates-clinical-trial-of-novel-upar-targeted-globenewswire 2024-10-07T12:09:56+00:00 weekly 0.7 https://trial.medpath.com/news/phio-announces-data-showcasing-intasyl-s-role-in-helping-immune-cells-target-and-kill 2024-10-07T12:05:57+00:00 weekly 0.7 https://trial.medpath.com/news/halia-therapeutics-announces-first-healthy-volunteer-dosed-with-ht-4253-a-novel-oral 2024-10-07T12:04:06+00:00 weekly 0.7 https://trial.medpath.com/news/bionomics-issues-shareholder-letter-highlighting-recent-achievements-and-strategic-vision 2024-10-07T12:02:19+00:00 weekly 0.7 https://trial.medpath.com/news/cytomed-therapeutics-first-in-human-phase-i-angelica-clinical-trial-using-its-patented-donor 2024-10-07T12:00:10+00:00 weekly 0.7 https://trial.medpath.com/news/brainstorm-cell-therapeutics-to-provide-corporate-update-on-phase-3b-nurown-r-trial-at 2024-10-07T11:52:04+00:00 weekly 0.7 https://trial.medpath.com/news/prescription-digital-therapeutics-addressing-unmet-needs-among-patients-with-mental 2024-10-07T11:47:19+00:00 weekly 0.7 https://trial.medpath.com/news/advancements-in-early-detection-and-innovative-therapies-targeting-tau-pathology 2024-10-07T11:46:20+00:00 weekly 0.7 https://trial.medpath.com/news/intellia-therapeutics-announces-initiation-of-haelo-phase-3-study-of-ntla-2002-an-stock-titan 2024-10-07T11:40:15+00:00 weekly 0.7 https://trial.medpath.com/news/hybrytetm-expanded-treatment-results-to-be-presented-at-the-european-organisation-for 2024-10-07T11:34:51+00:00 weekly 0.7 https://trial.medpath.com/news/biodesix-announces-new-data-presentation-at-chest-2024-annual-meeting-and-the-biospace 2024-10-07T11:15:55+00:00 weekly 0.7 https://trial.medpath.com/news/virios-therapeutics-inc-and-wex-pharmaceuticals-inc-globenewswire 2024-10-07T11:08:03+00:00 weekly 0.7 https://trial.medpath.com/news/inspiremd-announces-approval-of-investigational-device-exemption-ide-application-for 2024-10-07T11:07:20+00:00 weekly 0.7 https://trial.medpath.com/news/cytomed-therapeutics-first-in-human-phase-i-angelica-globenewswire 2024-10-07T11:04:21+00:00 weekly 0.7 https://trial.medpath.com/news/compound-discovered-at-university-of-montana-making-next-steps-in-cancer-trials 2024-10-07T10:37:49+00:00 weekly 0.7 https://trial.medpath.com/news/engineered-microparticles-modulate-arginine-metabolism-to-repolarize-tumor-associated 2024-10-07T10:37:41+00:00 weekly 0.7 https://trial.medpath.com/news/ferring-bolsters-adstiladrin-production-with-finland-expansion-bioprocess-international 2024-10-07T10:25:55+00:00 weekly 0.7 https://trial.medpath.com/news/bright-light-therapy-may-ease-multiple-forms-of-depression 2024-10-07T10:10:56+00:00 weekly 0.7 https://trial.medpath.com/news/tumor-fraction-based-prognostic-tool-for-cancer-patients-referred-to-early-phase-clinical-trials 2024-10-07T09:53:23+00:00 weekly 0.7 https://trial.medpath.com/news/medinol-announces-first-in-human-implantation-of-drug-eluting-peripheral-stent-in-australia 2024-10-07T09:52:37+00:00 weekly 0.7 https://trial.medpath.com/news/fda-warning-letters-september-2024-edition-the-medicine-maker 2024-10-07T09:47:41+00:00 weekly 0.7 https://trial.medpath.com/news/blue-shield-of-california-slashes-humira-biosimilar-price-by-75-through-direct-purchase-model 2024-10-07T09:47:08+00:00 weekly 0.7 https://trial.medpath.com/news/onkure-and-reneo-pharmaceuticals-complete-merger 2024-10-07T09:01:09+00:00 weekly 0.7 https://trial.medpath.com/news/bedaquiline-versus-injectable-containing-regimens-for-rifampicin-resistant-and-multidrug 2024-10-07T08:34:33+00:00 weekly 0.7 https://trial.medpath.com/news/cd7-car-t-cell-therapy-shows-promise-for-leukaemia-pharmaceutical-technology 2024-10-07T08:25:48+00:00 weekly 0.7 https://trial.medpath.com/news/hugel-accelerates-global-expansion-of-botulinum-toxin-letybo-businesskorea 2024-10-07T08:16:59+00:00 weekly 0.7 https://trial.medpath.com/news/hansa-biopharma-s-hnsa-5487-achieved-rapid-and-highly-robust-igg-reduction-by-more 2024-10-07T08:12:36+00:00 weekly 0.7 https://trial.medpath.com/news/wellcome-leap-announces-phase-2-finalists-for-quantum-health-challenge 2024-10-07T08:10:51+00:00 weekly 0.7 https://trial.medpath.com/news/news-highlight-crispr-reduces-the-cause-of-blindness-in-monkeys-but-comes-with-toxicity 2024-10-07T08:05:30+00:00 weekly 0.7 https://trial.medpath.com/news/health-canada-approves-label-expansion-for-telix-s-illuccix-r-to-include-patient-selection 2024-10-07T07:58:51+00:00 weekly 0.7 https://trial.medpath.com/news/will-enanta-pharma-breathe-easy-rttnews 2024-10-07T07:57:50+00:00 weekly 0.7 https://trial.medpath.com/news/wockhardt-s-new-antibiotic-wck-6777-gains-fda-fast-track-status-completes-phase-i-trial 2024-10-07T07:49:16+00:00 weekly 0.7 https://trial.medpath.com/news/ushering-in-a-new-era-of-fit-for-purpose-clinical-endpoints-for-rett-syndrome 2024-10-07T07:21:58+00:00 weekly 0.7 https://trial.medpath.com/news/pulsesight-therapeutics-to-present-data-on-pst-611-at-ever-congress-2024 2024-10-07T07:06:34+00:00 weekly 0.7 https://trial.medpath.com/news/biosergen-completes-enrollment-of-first-cohort-in-bsg005-proof-of-concept-trial 2024-10-07T06:48:04+00:00 weekly 0.7 https://trial.medpath.com/news/ge-healthcare-announces-phase-i-results-for-a-first-of-its-kind-macrocyclic-manganese 2024-10-07T06:44:48+00:00 weekly 0.7 https://trial.medpath.com/news/avillion-announces-positive-high-level-results-from-phase-globenewswire 2024-10-07T06:26:50+00:00 weekly 0.7 https://trial.medpath.com/news/feasibility-of-interdisciplinary-evaluation-in-non-arthritic-hip-pain-a-randomized-trial 2024-10-07T06:21:09+00:00 weekly 0.7 https://trial.medpath.com/news/new-clinical-trial-to-prevent-food-allergies-in-children-opens-king-s-college-london 2024-10-07T06:15:48+00:00 weekly 0.7 https://trial.medpath.com/news/imu-biosciences-joins-ground-breaking-uk-research-globenewswire 2024-10-07T06:06:19+00:00 weekly 0.7 https://trial.medpath.com/news/airsupra-demonstrated-statistically-significant-and-clinically-meaningful-reduction-in-the-risk 2024-10-07T06:05:47+00:00 weekly 0.7 https://trial.medpath.com/news/addition-to-scientific-advisory-board-company-announcement-investegate 2024-10-07T06:03:11+00:00 weekly 0.7 https://trial.medpath.com/news/formulary-barriers-and-rebate-structures-hinder-adalimumab-biosimilar-adoption-in-us-market 2024-10-07T05:02:00+00:00 weekly 0.7 https://trial.medpath.com/news/evaluating-faricimab-in-treatment-naive-neovascular-age-related-macular-degeneration 2024-10-07T04:31:58+00:00 weekly 0.7 https://trial.medpath.com/news/a-novel-procedure-for-treating-radial-keratotomy-rk-induced-corneal-opth 2024-10-07T04:31:58+00:00 weekly 0.7 https://trial.medpath.com/news/can-cb1-inhibitors-make-a-comeback-in-obesity-biospace 2024-10-07T04:27:08+00:00 weekly 0.7 https://trial.medpath.com/news/viiv-healthcare-triples-hiv-prevention-drug-supply-for-low-income-nations 2024-10-07T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/renal-denervation-up-to-date-2024-evidence-and-perspectives-in-japan-nature 2024-10-07T03:55:30+00:00 weekly 0.7 https://trial.medpath.com/news/concerns-have-been-raised-about-obesity-treatments-which-are-attracting-attention-due-to-the-effect 2024-10-07T02:45:01+00:00 weekly 0.7 https://trial.medpath.com/news/productlife-group-expands-drug-development-capabilities-with-intiquan-acquisition 2024-10-07T02:29:35+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-use-of-up-to-three-tubes-of-biofrontera-inc-s-ameluz-aminolevulinic-acid-hci-topical-gel-10-in-one-treatment 2024-10-07T02:10:51+00:00 weekly 0.7 https://trial.medpath.com/news/preventing-antimicrobial-resistance-not-states-centre-may-approve-new-antibiotics-blue 2024-10-07T01:41:56+00:00 weekly 0.7 https://trial.medpath.com/news/health-check-long-suffering-mesoblast-investors-dare-to-dream-stockhead 2024-10-07T01:04:08+00:00 weekly 0.7 https://trial.medpath.com/news/rhythm-biosciences-2g-colostat-colorectal-cancer-detection-kit-outperforms-predecessor 2024-10-07T00:27:21+00:00 weekly 0.7 https://trial.medpath.com/news/mrna-licensing-deals-surge-to-3-8-billion-as-major-pharma-companies-bet-on-technology-s-future 2024-10-07T00:12:31+00:00 weekly 0.7 https://trial.medpath.com/news/leo-pharma-s-temtokibart-shows-comparable-efficacy-to-dupilumab-in-phase-2a-atopic-dermatitis-trial 2024-10-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/simtra-biopharma-solutions-invests-14m-to-expand-adc-manufacturing-capabilities 2024-10-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/heparegenix-raises-eur15-million-series-c-round-to 2024-10-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/efficacy-and-safety-of-gene-therapy-with-onasemnogene 2024-10-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/immuron-welcomes-nmrc-results-for-campylobacter-in-controlled-human-infection-model-study 2024-10-06T23:10:41+00:00 weekly 0.7 https://trial.medpath.com/news/personalised-radiotherapy-for-people-with-bladder-cancer-shows-promise 2024-10-06T23:01:55+00:00 weekly 0.7 https://trial.medpath.com/news/judo-bio-launches-with-100m-to-pioneer-kidney-targeted-rna-therapeutics 2024-10-06T23:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/abivax-enrols-first-participant-in-phase-iib-crohn-s-disease-drug-trial-msn 2024-10-06T21:36:05+00:00 weekly 0.7 https://trial.medpath.com/news/sammy-basso-progeria-advocate-has-died-at-28-stat-news 2024-10-06T21:14:40+00:00 weekly 0.7 https://trial.medpath.com/news/strategic-approaches-to-safety-profile-development-in-rare-disease-clinical-trials 2024-10-06T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/biomarker-testing-crucial-for-personalized-treatment-in-metastatic-nsclc-experts-emphasize 2024-10-06T20:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/arca-receives-fda-fast-track-designation-for-gencarotm-development-quick-facts 2024-10-06T19:49:27+00:00 weekly 0.7 https://trial.medpath.com/news/rheumatology-month-in-review-september-2024-hcplive 2024-10-06T19:24:30+00:00 weekly 0.7 https://trial.medpath.com/news/india-denies-clinical-trial-waivers-for-in-vitro-diagnostics-despite-global-approvals 2024-10-06T19:10:22+00:00 weekly 0.7 https://trial.medpath.com/news/european-commission-grants-nlx-112-orphan-medicinal-product-designation-neurologylive 2024-10-06T19:05:23+00:00 weekly 0.7 https://trial.medpath.com/news/new-drug-to-combat-debilitating-immune-system-disorder-lupus-the-condition-that-left-seal-scarred 2024-10-06T18:23:37+00:00 weekly 0.7 https://trial.medpath.com/news/policy-support-important-as-india-largely-an-out-of-pocket-market-panchal 2024-10-06T17:37:47+00:00 weekly 0.7 https://trial.medpath.com/news/sun-pharmaceutical-industry-gets-cdsco-panel-nod-to-study-aflibercept-injection 2024-10-06T17:25:32+00:00 weekly 0.7 https://trial.medpath.com/news/aim-vaccine-co-ltd-announces-unblinding-of-data-from-phase-iii-clinical-trial-of-iterative 2024-10-06T16:08:37+00:00 weekly 0.7 https://trial.medpath.com/news/glp-1-receptor-agonists-are-a-transformative-prehabilitation-tool-for-weight-loss-in-obese 2024-10-06T15:42:59+00:00 weekly 0.7 https://trial.medpath.com/news/mitsubishi-tanabe-pharma-america-to-present-radicava-ors-r-edaravone-pr-newswire 2024-10-06T14:53:30+00:00 weekly 0.7 https://trial.medpath.com/news/science-medicine-studying-the-chemical-miscommunication-that-may-lead-to-obesity 2024-10-06T14:05:45+00:00 weekly 0.7 https://trial.medpath.com/news/human-papillomavirus-hpv-induced-cancers-first-patient-enrolled-in-phase-i-iia-clinical-trial 2024-10-06T14:04:01+00:00 weekly 0.7 https://trial.medpath.com/news/london-clinical-trial-targets-lingering-covid-toll-on-patients-smell-distortion 2024-10-06T14:03:05+00:00 weekly 0.7 https://trial.medpath.com/news/medication-increases-radiation-therapy-s-efficacy-for-lung-cancer-that-has-progressed-to-brain 2024-10-06T13:42:40+00:00 weekly 0.7 https://trial.medpath.com/news/cedric-pobel-md-phenotypic-and-genomic-analyses-from-peace-1-in-de-novo-mcspc 2024-10-06T13:21:54+00:00 weekly 0.7 https://trial.medpath.com/news/immix-and-nexcella-make-progress-in-us-trial-for-light-chain-amyloidosis-car-t-nxc-201 2024-10-06T13:09:06+00:00 weekly 0.7 https://trial.medpath.com/news/fractional-doses-of-pneumococcal-vaccine-could-bolster-supply-in-under-resourced-regions 2024-10-06T12:48:13+00:00 weekly 0.7 https://trial.medpath.com/news/otsuka-reports-data-from-phase-iii-alzheimer-s-agitation-trial-msn 2024-10-06T12:35:26+00:00 weekly 0.7 https://trial.medpath.com/news/tifr-study-uses-psychedelic-drug-to-trace-neuron-that-can-reduce-anxiety-times-of-india 2024-10-06T09:22:43+00:00 weekly 0.7 https://trial.medpath.com/news/icmr-to-study-efficacy-of-metformin-inositol-in-pcos-treatment-the-economic-times 2024-10-06T04:46:35+00:00 weekly 0.7 https://trial.medpath.com/news/meta-correlation-of-the-effect-of-ketamine-and-psilocybin-induced-subjective-effects-on 2024-10-06T03:37:31+00:00 weekly 0.7 https://trial.medpath.com/news/tailored-chemotherapy-doses-lead-to-better-outcomes-in-high-risk-breast-cancer 2024-10-06T03:01:25+00:00 weekly 0.7 https://trial.medpath.com/news/deadly-venom-of-funnel-web-spiders-used-to-develop-breakthrough-drug-for-heart-attack-patients 2024-10-06T02:53:48+00:00 weekly 0.7 https://trial.medpath.com/news/nme8-is-essential-for-protection-against-chemotherapy-drug-cisplatin-induced-male 2024-10-06T01:56:07+00:00 weekly 0.7 https://trial.medpath.com/news/new-lung-cancer-drug-offers-hope-as-precision-medicine-advances-shia-waves 2024-10-06T01:20:45+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-and-immune-responses-to-neoadjuvant-fulvestrant-with-or-without-enzalutamide-in-er-her2 2024-10-06T01:20:03+00:00 weekly 0.7 https://trial.medpath.com/news/world-first-cancer-treatment-now-accessible-for-hundreds-more-aussies-as-prices-slashed 2024-10-06T01:03:02+00:00 weekly 0.7 https://trial.medpath.com/news/eu-the-johnson-and-johnson-vaccine-has-a-possible-link-with-blood-clotting-telegraph 2024-10-06T00:23:05+00:00 weekly 0.7 https://trial.medpath.com/news/research-seeks-to-establish-the-efficacy-of-minimally-invasive-breast-cancer-procedures-and-tests 2024-10-05T22:06:17+00:00 weekly 0.7 https://trial.medpath.com/news/pelabresib-and-ruxolitinib-show-benefit-in-treating-patients-with-jak-inhibitor-naive-myelofibrosis 2024-10-05T22:04:37+00:00 weekly 0.7 https://trial.medpath.com/news/lenacapavir-a-breakthrough-in-hiv-prevention-but-challenges-in-access-remai 2024-10-05T21:52:36+00:00 weekly 0.7 https://trial.medpath.com/news/exploring-the-use-of-ultra-hypofractionated-rt-in-elderly-breast-cancer 2024-10-05T21:38:12+00:00 weekly 0.7 https://trial.medpath.com/news/relationship-between-sleep-and-pain-the-hippocratic-post 2024-10-05T21:25:59+00:00 weekly 0.7 https://trial.medpath.com/news/u-of-virginia-researchers-explore-new-ways-to-manage-diabetes-wtop-news 2024-10-05T20:52:19+00:00 weekly 0.7 https://trial.medpath.com/news/a-phase-1-first-in-human-study-evaluating-safety-pharmacokinetics-and-efficacy-of-abbv 2024-10-05T20:03:45+00:00 weekly 0.7 https://trial.medpath.com/news/top-5-infectious-disease-news-stories-week-of-september-27-october-4-contagion-live 2024-10-05T19:42:38+00:00 weekly 0.7 https://trial.medpath.com/news/vamorolone-shows-potential-dual-mechanism-as-mineralcorticoid-receptor-antagonist-in 2024-10-05T19:04:54+00:00 weekly 0.7 https://trial.medpath.com/news/suven-life-sciences-to-present-positive-results-from-phase-2a-proof-of-concept-study-of-ropanicant 2024-10-05T17:32:07+00:00 weekly 0.7 https://trial.medpath.com/news/how-doctors-hope-new-cannabis-drug-will-help-cancer-patients-gain-weight-inews 2024-10-05T17:24:57+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-gets-fda-approval-for-pnh-drug-voydeya-msn 2024-10-05T17:17:04+00:00 weekly 0.7 https://trial.medpath.com/news/horizon-study-update-for-msa-drug-ion464-onaboutlinumtoxina-to-be-tested-in-essential 2024-10-05T17:07:30+00:00 weekly 0.7 https://trial.medpath.com/news/treatment-persistence-safety-after-switching-to-infliximab-biosimilars-in-canadians-with-ibd 2024-10-05T17:06:45+00:00 weekly 0.7 https://trial.medpath.com/news/this-healthcare-growth-stock-could-be-a-steal-of-a-deal-right-now-the-globe-and-mail 2024-10-05T16:43:06+00:00 weekly 0.7 https://trial.medpath.com/news/new-gsk-pfizer-moderna-rsv-vaccines-available-for-older-adults-60-fortune-well 2024-10-05T16:27:08+00:00 weekly 0.7 https://trial.medpath.com/news/urinary-cyclophilin-a-as-an-early-marker-of-chronic-kidney-disease-with-underlying-type-2-diabetes 2024-10-05T16:15:30+00:00 weekly 0.7 https://trial.medpath.com/news/rural-iowa-mothers-face-severe-postpartum-depression-news-kmaland-com 2024-10-05T14:50:29+00:00 weekly 0.7 https://trial.medpath.com/news/secukinumab-surpasses-ustekinumab-in-clearing-skin-for-generalized-pustular-psoriasis 2024-10-05T14:42:34+00:00 weekly 0.7 https://trial.medpath.com/news/new-drug-could-extend-the-lives-of-breast-cancer-patients-news-medical 2024-10-05T14:02:50+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trials-of-india-s-first-covid-19-vaccine-to-start-with-375-people-the-commune 2024-10-05T13:54:16+00:00 weekly 0.7 https://trial.medpath.com/news/1-ai-biotech-stock-that-just-scored-a-major-milestone-the-globe-and-mail 2024-10-05T12:36:26+00:00 weekly 0.7 https://trial.medpath.com/news/j-j-discontinues-study-for-investigational-antiviral-for-dengue-prevention-contagion-live 2024-10-05T10:52:31+00:00 weekly 0.7 https://trial.medpath.com/news/department-of-defense-funded-research-may-lea-eurekalert 2024-10-05T09:31:36+00:00 weekly 0.7 https://trial.medpath.com/news/matching-adjusted-indirect-comparison-of-the-efficacy-and-safety-of-difamilast-1-and 2024-10-05T09:05:05+00:00 weekly 0.7 https://trial.medpath.com/news/vaccine-trial-stalls-due-to-fund-crunch-the-daily-star 2024-10-05T08:12:15+00:00 weekly 0.7 https://trial.medpath.com/news/ge-healthcare-receives-fda-clearance-for-alzheimer-s-imaging-tool-hit-consultant 2024-10-05T08:10:42+00:00 weekly 0.7 https://trial.medpath.com/news/cgtlive-r-s-weekly-rewind-october-4-2024 2024-10-05T07:08:57+00:00 weekly 0.7 https://trial.medpath.com/news/valbenazine-shows-sustained-treatment-effect-on-huntington-s-chorea-in-kinect-hd2 2024-10-05T07:05:13+00:00 weekly 0.7 https://trial.medpath.com/news/neurologylive-r-friday-5-october-4-2024 2024-10-05T07:05:11+00:00 weekly 0.7 https://trial.medpath.com/news/novel-anti-estrogen-therapies-are-poised-to-expand-treatment-options-in-advanced-er 2024-10-05T06:40:05+00:00 weekly 0.7 https://trial.medpath.com/news/inside-information-bioretec-updates-its-product-development-strategy-by-accelerating-the 2024-10-05T06:34:44+00:00 weekly 0.7 https://trial.medpath.com/news/groundbreaking-drug-could-make-tooth-loss-a-thing-of-the-past-by-2030-news18 2024-10-05T05:21:57+00:00 weekly 0.7 https://trial.medpath.com/news/ai-pos-and-roi-an-alphabet-soup-of-21st-century-drug-development-life-science-leader 2024-10-05T05:19:12+00:00 weekly 0.7 https://trial.medpath.com/news/dear-payers-people-living-with-early-alzheimer-s-disease-are-worth-it-medical-economics 2024-10-05T05:09:05+00:00 weekly 0.7 https://trial.medpath.com/news/q-a-roflumilast-cream-0-15-for-ad-with-eric-simpson-md-mcr-faad 2024-10-05T05:07:15+00:00 weekly 0.7 https://trial.medpath.com/news/i-spy-2-2-is-working-why-aren-t-others-replicating-the-design-biocentury 2024-10-05T05:06:33+00:00 weekly 0.7 https://trial.medpath.com/news/atezolizumab-plus-platinum-doublet-and-maintenance-niraparib-for-late-relapsing 2024-10-05T04:01:28+00:00 weekly 0.7 https://trial.medpath.com/news/9-months-of-treatment-with-tralokinumab-results-in-improved-qol-itch-and-sleep 2024-10-05T03:47:54+00:00 weekly 0.7 https://trial.medpath.com/news/an-investigator-s-perspective-on-biomarker-guided-antibiotic-treatment-contagion-live 2024-10-05T03:32:29+00:00 weekly 0.7 https://trial.medpath.com/news/gut-bacteria-engineered-to-act-as-tumor-gps-for-immunotherapies-medical-xpress 2024-10-05T03:30:50+00:00 weekly 0.7 https://trial.medpath.com/news/relay-therapeutics-to-lay-off-10-of-workforce-biospace 2024-10-05T03:24:46+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-relapsed-or-refractory-acute-lymphocytic-leukemia-all-nct06481735 2024-10-05T01:53:18+00:00 weekly 0.7 https://trial.medpath.com/news/kineta-announces-kva12123-abstract-accepted-for-poster-globenewswire 2024-10-05T01:07:32+00:00 weekly 0.7 https://trial.medpath.com/news/oral-paltusotine-demonstrates-efficacy-in-phase-3-acromegaly-trial-offering-alternative-to-injectable-treatments 2024-10-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-blood-test-improves-early-diagnosis-of-pancreatic-cancer-news-medical 2024-10-04T23:41:44+00:00 weekly 0.7 https://trial.medpath.com/news/why-avidity-biosciences-zoomed-to-a-12-gain-this-week-the-globe-and-mail 2024-10-04T23:20:14+00:00 weekly 0.7 https://trial.medpath.com/news/avidity-biosciences-rna-stock-surges-on-fda-decision-gurufocus 2024-10-04T23:01:00+00:00 weekly 0.7 https://trial.medpath.com/news/boy-with-duchenne-s-gets-gene-therapy-3-days-before-he-s-ineligible-exclusive 2024-10-04T22:40:49+00:00 weekly 0.7 https://trial.medpath.com/news/novel-radioconjugate-or-conventional-care-prior-to-allogeneic-hematopoietic-cell 2024-10-04T22:37:33+00:00 weekly 0.7 https://trial.medpath.com/news/tranexamic-acid-during-radical-cystectomy-a-randomized-clinical-trial-urotoday 2024-10-04T22:30:20+00:00 weekly 0.7 https://trial.medpath.com/news/nivolumab-rt-improves-biochemical-recurrence-outcomes-in-prostate-cancer 2024-10-04T21:53:08+00:00 weekly 0.7 https://trial.medpath.com/news/island-pharmaceuticals-trials-prevention-and-therapy-benefit-of-dengue-drug 2024-10-04T21:10:29+00:00 weekly 0.7 https://trial.medpath.com/news/dr-machaalani-on-the-incidence-of-erbb2-amplifications-across-race-sex-and-cancer-type 2024-10-04T21:07:47+00:00 weekly 0.7 https://trial.medpath.com/news/cms-initiates-coverage-review-for-abbott-triclip-system-massdevice 2024-10-04T18:59:58+00:00 weekly 0.7 https://trial.medpath.com/news/aulos-bioscience-to-present-promising-phase-2-data-for-novel-il-2-therapeutic-antibody 2024-10-04T18:42:48+00:00 weekly 0.7 https://trial.medpath.com/news/ema-reviews-hair-loss-products-following-concerns-about-suicidal-thoughts 2024-10-04T18:28:07+00:00 weekly 0.7 https://trial.medpath.com/news/plasma-egfr-mutation-ctdna-dynamics-in-patients-with-advanced-egfr-mutated-nsclc 2024-10-04T17:37:36+00:00 weekly 0.7 https://trial.medpath.com/news/onco360-r-has-been-selected-as-the-national-specialty-pharmacy-partner-for-tevimbra 2024-10-04T17:32:06+00:00 weekly 0.7 https://trial.medpath.com/news/opdivo-gets-perioperative-approval-pharmas-cut-jobs-in-new-jersey-ireland 2024-10-04T17:16:16+00:00 weekly 0.7 https://trial.medpath.com/news/oncolytics-biotech-r-announces-key-progress-and-upcoming-studies-for-breast-pr-newswire 2024-10-04T17:00:48+00:00 weekly 0.7 https://trial.medpath.com/news/global-mrna-cancer-vaccine-clinical-trial-fda-approval-globenewswire 2024-10-04T16:56:58+00:00 weekly 0.7 https://trial.medpath.com/news/studying-a-culturally-tailored-anti-inflammatory-diet-s-impact-on-hispanic-latinx-patients 2024-10-04T16:49:14+00:00 weekly 0.7 https://trial.medpath.com/news/alpha-cognition-announces-executive-shake-up-drug-approval-tipranks-com 2024-10-04T16:40:39+00:00 weekly 0.7 https://trial.medpath.com/news/an-alzheimer-s-drugmaker-is-accused-of-data-manipulation-should-its-trials-be-stopped 2024-10-04T16:37:19+00:00 weekly 0.7 https://trial.medpath.com/news/affimed-n-v-advances-in-clinical-development-of-novel-therapies-for-solid-and-liquid-tumors 2024-10-04T16:35:04+00:00 weekly 0.7 https://trial.medpath.com/news/magic-g1-study-provides-updated-findings-with-mtx110-in-recurrent-glioblastoma 2024-10-04T16:09:53+00:00 weekly 0.7 https://trial.medpath.com/news/pen-bay-waldo-expand-cardiac-rehab-offerings-mainehealth 2024-10-04T16:08:39+00:00 weekly 0.7 https://trial.medpath.com/news/highlights-in-non-prostate-gu-oncology-from-esmo-2024-ignacio-duran-urotoday 2024-10-04T16:03:02+00:00 weekly 0.7 https://trial.medpath.com/news/alembic-receives-usfda-final-approval-for-alcaftadine-ophthalmic-solution-0-25-otc 2024-10-04T15:53:10+00:00 weekly 0.7 https://trial.medpath.com/news/chronic-urticaria-competitive-landscape-assessment-2024-globenewswire 2024-10-04T15:47:52+00:00 weekly 0.7 https://trial.medpath.com/news/variation-in-opioid-agonist-dosing-in-clinical-trials-by-race-and-ethnicity-jama-network 2024-10-04T15:37:55+00:00 weekly 0.7 https://trial.medpath.com/news/lanzatech-to-produce-30000-tonnes-of-microbial-protein-per-annum-the-fish-site 2024-10-04T15:30:57+00:00 weekly 0.7 https://trial.medpath.com/news/vividion-continues-to-teach-covalent-compounds-new-tricks 2024-10-04T15:20:38+00:00 weekly 0.7 https://trial.medpath.com/news/case-report-allogeneic-culture-expanded-bone-marrow-derived-mesenchymal-stem-cells-for 2024-10-04T15:04:43+00:00 weekly 0.7 https://trial.medpath.com/news/myeloproliferative-neoplasms-treatment-new-insights-hematology-advisor 2024-10-04T15:02:25+00:00 weekly 0.7 https://trial.medpath.com/news/tiumbio-announces-first-patient-dosed-in-phase-2-clinical-trial-of-oral-immuno-oncology 2024-10-04T15:01:26+00:00 weekly 0.7 https://trial.medpath.com/news/amazing-trial-shows-drug-combination-stops-lung-cancer-advancing-for-longer 2024-10-04T14:51:10+00:00 weekly 0.7 https://trial.medpath.com/news/wuxi-companies-consider-asset-sales-amid-us-biosecure-act-pressure 2024-10-04T14:46:55+00:00 weekly 0.7 https://trial.medpath.com/news/summit-therapeutics-stock-jumps-as-lung-cancer-drug-placed-on-fda-fast-track 2024-10-04T14:14:09+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-16-new-cancer-treatments-as-global-cancer-rates-skyrocket-kilgore-news-herald 2024-10-04T14:10:22+00:00 weekly 0.7 https://trial.medpath.com/news/indoco-remedies-receives-u-s-fda-approval-for-generic-cetirizine-tablets 2024-10-04T13:44:47+00:00 weekly 0.7 https://trial.medpath.com/news/a-compound-analysis-of-medical-device-clinical-trials-registered-in-africa-on-clinicaltrials-gov 2024-10-04T13:32:24+00:00 weekly 0.7 https://trial.medpath.com/news/emavusertib-focused-research-is-poised-to-expand-the-pcnsl-treatment-paradigm 2024-10-04T13:24:40+00:00 weekly 0.7 https://trial.medpath.com/news/turkey-brazil-emerging-as-clinical-trial-destinations-for-cancer-drugs-biospace 2024-10-04T13:10:35+00:00 weekly 0.7 https://trial.medpath.com/news/h-c-wainwright-keeps-buy-rating-on-summit-therapeutics-stock-highlighting-fast-track-designation 2024-10-04T13:08:27+00:00 weekly 0.7 https://trial.medpath.com/news/cytodyn-engages-syneos-health-as-cro-for-its-phase-ii-oncology-trial 2024-10-04T12:50:22+00:00 weekly 0.7 https://trial.medpath.com/news/the-first-six-months-of-the-2024-voluntary-scheme 2024-10-04T12:38:48+00:00 weekly 0.7 https://trial.medpath.com/news/trevi-therapeutics-provides-update-on-haduvio-s-clinical-development-program 2024-10-04T12:38:43+00:00 weekly 0.7 https://trial.medpath.com/news/biodexa-provides-update-on-progression-free-and-overall-globenewswire 2024-10-04T12:34:00+00:00 weekly 0.7 https://trial.medpath.com/news/sapience-therapeutics-announces-participation-at-the-4th-annual-needham-private-biotech 2024-10-04T12:32:22+00:00 weekly 0.7 https://trial.medpath.com/news/treatment-selection-landscape-evolves-for-egfr-nsclc-with-new-therapeutic-options 2024-10-04T12:18:25+00:00 weekly 0.7 https://trial.medpath.com/news/avistone-announces-updates-on-ans014004-yahoo-finance 2024-10-04T12:16:26+00:00 weekly 0.7 https://trial.medpath.com/news/creation-of-de-novo-cryptic-splicing-for-als-and-ftd-precision-medicine-pubmed 2024-10-04T11:51:00+00:00 weekly 0.7 https://trial.medpath.com/news/oxcia-is-focusing-the-development-of-oxc-101-on-hematological-cancers-cision-news 2024-10-04T11:33:02+00:00 weekly 0.7 https://trial.medpath.com/news/hepatocellular-carcinoma-clinical-trials-2024-ema-pdma-fda-openpr-com 2024-10-04T11:30:51+00:00 weekly 0.7 https://trial.medpath.com/news/pompe-disease-clinical-trials-2024-updates-ema-pdma-fda-openpr-com 2024-10-04T11:27:21+00:00 weekly 0.7 https://trial.medpath.com/news/turkish-nobel-scientist-aziz-sancar-s-brain-cancer-breakthrough-enters-human-trials 2024-10-04T11:19:59+00:00 weekly 0.7 https://trial.medpath.com/news/anti-cd70-antibodies-clinical-trials-fda-approval-cd70-globenewswire 2024-10-04T11:16:24+00:00 weekly 0.7 https://trial.medpath.com/news/global-lag-3-antibody-fda-approval-clinical-trials-lag-3-globenewswire 2024-10-04T11:16:22+00:00 weekly 0.7 https://trial.medpath.com/news/airdrie-family-seeks-support-for-potential-life-saving-drug-trial-in-the-u-s 2024-10-04T11:10:51+00:00 weekly 0.7 https://trial.medpath.com/news/ideaya-biosciences-announces-late-breaker-oral-presentation-of-ide397-phase-1-quantisnow 2024-10-04T10:18:11+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-exact-sciences-cologuard-plus-test-setting-a-new-benchmark-in-non 2024-10-04T10:10:57+00:00 weekly 0.7 https://trial.medpath.com/news/mpox-vaccine-s-protection-wanes-within-1-year-boosters-needed 2024-10-04T09:10:32+00:00 weekly 0.7 https://trial.medpath.com/news/abl-bio-announces-clinical-collaboration-to-evaluate-abl103-in-combination-with-biospace 2024-10-04T08:07:18+00:00 weekly 0.7 https://trial.medpath.com/news/mckesson-launches-inspirogene-to-revolutionize-cell-and-gene-therapy-commercialization 2024-10-04T06:05:50+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-dual-approval-for-amivantamab-in-non-small-cell-lung-cancer-treatment 2024-10-04T05:52:19+00:00 weekly 0.7 https://trial.medpath.com/news/aldeyra-therapeutics-resubmits-new-drug-application-for-reproxalap-for-the-treatment-of-dry 2024-10-04T05:07:31+00:00 weekly 0.7 https://trial.medpath.com/news/breast-cancer-treatment-advances-drive-90-survival-rate-in-early-stage-disease-expert-highlights-progress 2024-10-04T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/alzheimer-s-mab-policies-do-not-set-precedent-for-accelerated-approval-cms-s-former-cmo-says 2024-10-04T04:24:38+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-presurgical-postsurgical-opdivo-for-nsclc-cure-today 2024-10-04T03:47:59+00:00 weekly 0.7 https://trial.medpath.com/news/ultragenyx-provides-update-on-stage-1-cohorts-in-pivotal-phase-1-2-3-cyprus2-study 2024-10-04T03:03:49+00:00 weekly 0.7 https://trial.medpath.com/news/international-experts-to-gather-for-als-symposium-in-chicago-news-medical 2024-10-04T02:42:33+00:00 weekly 0.7 https://trial.medpath.com/news/recordati-acquires-global-rights-to-sanofi-s-cad-treatment-enjaymo-in-825m-deal 2024-10-04T02:31:06+00:00 weekly 0.7 https://trial.medpath.com/news/cell-therapy-weekly-promising-phase-i-results-for-parkinson-s-disease-cell-therapy-regmednet 2024-10-04T01:31:53+00:00 weekly 0.7 https://trial.medpath.com/news/first-patient-dosed-achieves-complete-response-in-estrella-immunopharma-s-trial-for-cgtlive-r 2024-10-04T01:27:35+00:00 weekly 0.7 https://trial.medpath.com/news/neoadjuvant-toripalimab-plus-axitinib-for-clear-cell-renal-cell-carcinoma-with-inferior-vena 2024-10-04T01:15:31+00:00 weekly 0.7 https://trial.medpath.com/news/anvs-annovis-bio-inc-latest-stock-news-market-updates 2024-10-04T00:46:40+00:00 weekly 0.7 https://trial.medpath.com/news/abivax-announces-first-patient-enrolled-in-enhance-cd-the-phase-2b-trial-of-biospace 2024-10-04T00:40:12+00:00 weekly 0.7 https://trial.medpath.com/news/allegheny-general-hospital-among-nation-s-top-enrollment-sites-for-clinical-trial-exploring 2024-10-04T00:31:56+00:00 weekly 0.7 https://trial.medpath.com/news/world-first-ovarian-cancer-vaccine-being-developed-in-uk-the-independent 2024-10-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/palvella-therapeutics-awarded-up-to-2-6-million-grant-from-globenewswire 2024-10-03T23:32:13+00:00 weekly 0.7 https://trial.medpath.com/news/gastroenterology-month-in-review-september-2024-hcplive 2024-10-03T23:03:43+00:00 weekly 0.7 https://trial.medpath.com/news/cellprothera-begins-long-term-observational-study-to-demonstrate-safety-and-efficacy-of 2024-10-03T22:53:07+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-uva-health-tested-lung-cancer-treatment-wvir 2024-10-03T22:45:20+00:00 weekly 0.7 https://trial.medpath.com/news/steap1-targeted-t-cell-engager-demonstrates-efficacy-in-mcrpc-patients-william-kevin-kelly 2024-10-03T22:10:46+00:00 weekly 0.7 https://trial.medpath.com/news/cancer-program-receives-platinum-award-for-patient-participation-in-cancer-research 2024-10-03T21:30:13+00:00 weekly 0.7 https://trial.medpath.com/news/investigation-of-serum-neurofilament-light-chain-as-a-biomarker-in-fabry-disease-nature 2024-10-03T20:56:22+00:00 weekly 0.7 https://trial.medpath.com/news/nsf-nih-and-fda-support-research-in-digital-twin-technology-for-biomedical-applications 2024-10-03T20:53:41+00:00 weekly 0.7 https://trial.medpath.com/news/dr-girard-on-pros-from-the-luminosity-trial-in-c-met-overexpressing-nsclc-onclive 2024-10-03T19:46:47+00:00 weekly 0.7 https://trial.medpath.com/news/ge-healthcare-s-mim-software-wins-fda-clearance-for-monte-carlo-dosimetry-massdevice 2024-10-03T19:36:12+00:00 weekly 0.7 https://trial.medpath.com/news/future-of-oral-small-molecule-drugs-addressing-potential-in-multiple-sclerosis 2024-10-03T19:04:17+00:00 weekly 0.7 https://trial.medpath.com/news/grand-rounds-september-27-2024-azithromycin-for-childhood-mortality-rethinking-clinical-trials 2024-10-03T18:49:22+00:00 weekly 0.7 https://trial.medpath.com/news/phase-iii-trial-fedratinib-reduces-spleen-size-in-ruxolitinib-refractory-myelofibrosis 2024-10-03T18:43:26+00:00 weekly 0.7 https://trial.medpath.com/news/nhs-england-proposes-phased-launch-of-obesity-injection-pf-media 2024-10-03T18:36:13+00:00 weekly 0.7 https://trial.medpath.com/news/stemcyte-s-hpc-cord-blood-receives-rmat-designation-for-long-covid-19-treatment 2024-10-03T18:13:15+00:00 weekly 0.7 https://trial.medpath.com/news/artax-biopharma-to-present-first-in-class-nck-modulator-mechanism-of-action-and-phase-1 2024-10-03T18:08:57+00:00 weekly 0.7 https://trial.medpath.com/news/recent-clinical-data-confirms-significantly-improved-predictive-power-of-evaxion-s-ai 2024-10-03T18:07:32+00:00 weekly 0.7 https://trial.medpath.com/news/calquence-granted-priority-review-in-the-us-for-patients-with-untreated-mantle-cell-lymphoma 2024-10-03T18:05:02+00:00 weekly 0.7 https://trial.medpath.com/news/ec-approves-daiichi-sankyo-s-vanflyta-for-acute-myeloid-leukaemia-msn 2024-10-03T17:55:55+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-breakthrough-device-designation-to-amphix-bio-s-bone-regeneration-product 2024-10-03T17:52:42+00:00 weekly 0.7 https://trial.medpath.com/news/therivatm-biologics-announces-positive-outcome-of-data-and-safety-monitoring-committee 2024-10-03T17:45:39+00:00 weekly 0.7 https://trial.medpath.com/news/long-term-trial-data-boosts-case-for-newer-drug-resistant-tb-regimens-cidrap 2024-10-03T17:19:28+00:00 weekly 0.7 https://trial.medpath.com/news/ketamine-pills-could-finally-offer-depression-breakthrough-miriam-stoppard-mirror-online 2024-10-03T17:14:21+00:00 weekly 0.7 https://trial.medpath.com/news/parkinson-s-therapy-nd0612-reduces-off-time-increases-on-time-after-a-year 2024-10-03T17:05:15+00:00 weekly 0.7 https://trial.medpath.com/news/virtual-family-centered-rounds-help-parents-support-their-child-s-care-uc-davis-health 2024-10-03T17:03:45+00:00 weekly 0.7 https://trial.medpath.com/news/alfasigma-receives-green-light-to-sell-jyseleca-in-europe-born2invest 2024-10-03T16:32:50+00:00 weekly 0.7 https://trial.medpath.com/news/nucleos-t-ide-analogs-to-treat-patients-with-positive-hepatitis-b-virus-deoxyribonucleic-acid 2024-10-03T16:28:46+00:00 weekly 0.7 https://trial.medpath.com/news/after-40m-settlement-alzheimer-s-drug-under-scrutiny-as-human-trials-proceed 2024-10-03T16:21:22+00:00 weekly 0.7 https://trial.medpath.com/news/assessment-of-antitachycardia-pacing-in-primary-prevention-patients-jama-network 2024-10-03T16:20:40+00:00 weekly 0.7 https://trial.medpath.com/news/emerging-dll3-targeted-therapies-demonstrate-efficacy-in-neuroendocrine-prostate-cancer 2024-10-03T16:13:43+00:00 weekly 0.7 https://trial.medpath.com/news/veracyte-s-rna-genetic-test-predicts-black-men-s-aggressive-prostate-cancer 2024-10-03T16:11:46+00:00 weekly 0.7 https://trial.medpath.com/news/six-biotechs-driving-progress-in-duchenne-muscular-dystrophy-labiotech-eu 2024-10-03T15:59:11+00:00 weekly 0.7 https://trial.medpath.com/news/can-eye-drops-replace-surgery-for-curing-cataracts-theu 2024-10-03T15:55:55+00:00 weekly 0.7 https://trial.medpath.com/news/adjuvant-nivolumab-vs-placebo-in-localized-renal-cell-carcinoma-at-high-risk-of 2024-10-03T15:53:29+00:00 weekly 0.7 https://trial.medpath.com/news/autologous-vs-allogeneic-stem-cell-transplantation-in-younger-patients-with-peripheral-t 2024-10-03T15:50:31+00:00 weekly 0.7 https://trial.medpath.com/news/calcium-carbonate-supplementation-for-the-prevention-of-preeclampsia-in-high-risk-pregnant-women 2024-10-03T15:38:39+00:00 weekly 0.7 https://trial.medpath.com/news/convalescent-plasma-might-have-saved-thousands-more-lives-during-covid-pandemic 2024-10-03T15:32:40+00:00 weekly 0.7 https://trial.medpath.com/news/stem-cell-therapy-might-repair-vision-robbing-holes-in-retinas 2024-10-03T15:10:36+00:00 weekly 0.7 https://trial.medpath.com/news/investigating-early-diagnosis-through-genomic-medicine-nhs-england 2024-10-03T15:03:47+00:00 weekly 0.7 https://trial.medpath.com/news/bayer-s-kerendia-demonstrates-success-in-phase-3-clinical-trials-for-treatment-of-heart-failure 2024-10-03T14:36:40+00:00 weekly 0.7 https://trial.medpath.com/news/tirzepatide-semaglutide-more-efficacious-than-other-fda-approved-drugs-for-weight-loss 2024-10-03T14:24:51+00:00 weekly 0.7 https://trial.medpath.com/news/peph-newsletter-october-2024-national-institute-of-environmental-health-sciences 2024-10-03T14:17:43+00:00 weekly 0.7 https://trial.medpath.com/news/first-line-versamune-hpv-vaccine-bolsters-responses-with-soc-pembrolizumab-in-onclive 2024-10-03T14:07:20+00:00 weekly 0.7 https://trial.medpath.com/news/genomic-testing-saved-my-life-illumina 2024-10-03T13:53:02+00:00 weekly 0.7 https://trial.medpath.com/news/mangorx-introduces-oral-tirzepatide-glp-1-receptor-agonist-for-advanced-weight-loss-solutions 2024-10-03T12:41:14+00:00 weekly 0.7 https://trial.medpath.com/news/elucid-scoops-fda-approval-for-ai-cardiovascular-risk-diagnostic-yahoo-finance 2024-10-03T12:32:56+00:00 weekly 0.7 https://trial.medpath.com/news/resolution-therapeutics-announces-ps63-5-million-series-b-financing-and-chair-appointment 2024-10-03T12:31:08+00:00 weekly 0.7 https://trial.medpath.com/news/bridgebio-to-present-outcomes-data-through-42-months-from-the-open-label-extension-of 2024-10-03T12:15:48+00:00 weekly 0.7 https://trial.medpath.com/news/immutep-completes-patient-enrolment-in-randomised-phase-ii-of-aipac-003-trial-in 2024-10-03T12:05:18+00:00 weekly 0.7 https://trial.medpath.com/news/major-alzheimer-s-breakthrough-as-experts-discover-double-whammy-drug-that-destroys 2024-10-03T12:04:37+00:00 weekly 0.7 https://trial.medpath.com/news/alembic-pharma-jumps-4-on-us-fda-approves-anti-seizure-drug-worth-163-million 2024-10-03T12:01:29+00:00 weekly 0.7 https://trial.medpath.com/news/new-jersey-biotech-reports-positive-survival-data-the-streetwise-reports 2024-10-03T11:17:40+00:00 weekly 0.7 https://trial.medpath.com/news/avidity-biosciences-announces-fda-removed-partial-clinical-hold-on-delpacibart 2024-10-03T11:15:40+00:00 weekly 0.7 https://trial.medpath.com/news/validation-of-a-digital-pathology-based-mmai-model-in-oligometastatic-castration-sensitive 2024-10-03T11:09:47+00:00 weekly 0.7 https://trial.medpath.com/news/first-patient-dosed-in-phase-ii-ca-nine-trial-of-tlx250-cdx-for-detection-of-recurrent 2024-10-03T11:07:46+00:00 weekly 0.7 https://trial.medpath.com/news/eye-on-pharma-high-strength-trastuzumab-biosimilar-originator-coverage-removals 2024-10-03T11:05:39+00:00 weekly 0.7 https://trial.medpath.com/news/rwanda-to-kick-off-vaccine-and-therapeutic-clinical-trials-for-marbug-disease-in-several-weeks 2024-10-03T11:02:44+00:00 weekly 0.7 https://trial.medpath.com/news/novavax-nvax-stock-rises-19-after-fda-approval-for-updated-covid-19-vaccine 2024-10-03T10:30:06+00:00 weekly 0.7 https://trial.medpath.com/news/could-lithium-supplements-ease-the-brain-fog-of-long-covid 2024-10-03T10:10:13+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approved-zunveyl-for-alzheimer-s-symptoms-on-the-way-in-2025-being-patient 2024-10-03T10:04:46+00:00 weekly 0.7 https://trial.medpath.com/news/datacc-by-dime-awarded-fda-grant-to-boost-use-of-sensor-based-digital-health 2024-10-03T09:51:02+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-to-invest-4-5bn-for-drug-manufacturing-and-trial-medicine-production 2024-10-03T09:25:28+00:00 weekly 0.7 https://trial.medpath.com/news/october-3-2024-jama-commentary-highlights-gap-between-research-results-and 2024-10-03T08:01:18+00:00 weekly 0.7 https://trial.medpath.com/news/phase-iii-randomized-clinical-trial-of-efficacy-and-safety-of-amlodipine-and-candesartan 2024-10-03T07:50:30+00:00 weekly 0.7 https://trial.medpath.com/news/bpd-maintains-qol-vs-pvd-supporting-its-use-as-a-new-soc-in-r-r-myeloma-onclive 2024-10-03T07:42:17+00:00 weekly 0.7 https://trial.medpath.com/news/korean-clinical-trials-prove-exosomes-peptides-and-spicules-outperforms-retinol-in-anti-ageing 2024-10-03T07:34:37+00:00 weekly 0.7 https://trial.medpath.com/news/new-research-targets-cognitive-recovery-after-brain-injury-rowan-today 2024-10-03T07:33:37+00:00 weekly 0.7 https://trial.medpath.com/news/revvity-s-euroimmun-launches-solution-for-specific-typing-of-alzheimer-s-disease-news-medical 2024-10-03T07:26:04+00:00 weekly 0.7 https://trial.medpath.com/news/radiopharm-closes-in-on-cancer-fighting-drug-approval-the-west-australian 2024-10-03T07:13:32+00:00 weekly 0.7 https://trial.medpath.com/news/mrd-negativity-is-sustained-after-cessation-of-lenalidomide-maintenance-in-multiple-myeloma 2024-10-03T07:09:10+00:00 weekly 0.7 https://trial.medpath.com/news/camber-pharmaceuticals-achieves-full-dscsa-compliance-ahead-of-2024-deadline 2024-10-03T07:06:40+00:00 weekly 0.7 https://trial.medpath.com/news/recipharm-expands-global-pharmaceutical-development-capabilities-with-strategic-investments 2024-10-03T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/gender-gap-in-heart-disease-women-face-higher-misdiagnosis-risks-and-mortality-rates 2024-10-03T06:32:39+00:00 weekly 0.7 https://trial.medpath.com/news/resolution-therapeutics-macrophage-therapy-raises-85-million-labiotech-eu 2024-10-03T06:32:33+00:00 weekly 0.7 https://trial.medpath.com/news/study-aims-to-resolve-variants-of-uncertain-significance 2024-10-03T05:00:04+00:00 weekly 0.7 https://trial.medpath.com/news/high-rates-of-polycythemia-vera-remission-seen-with-ruxolitinib-plus-peg-ifn 2024-10-03T03:27:45+00:00 weekly 0.7 https://trial.medpath.com/news/proscia-launches-ai-powered-pathology-platform-to-accelerate-precision-medicine-research 2024-10-03T01:15:56+00:00 weekly 0.7 https://trial.medpath.com/news/weight-loss-drugs-gene-therapies-clinical-trials-to-watch-right-now-quartz 2024-10-03T00:01:17+00:00 weekly 0.7 https://trial.medpath.com/news/fda-fully-revokes-authorization-of-gsk-and-vir-s 2024-10-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-t1d-and-integrated-nanotherapeutics-collaborate-to-advance-development 2024-10-02T23:35:22+00:00 weekly 0.7 https://trial.medpath.com/news/processa-pharmaceuticals-announces-first-patient-dosed-in-phase-2-clinical-trial-of-ngc 2024-10-02T23:22:07+00:00 weekly 0.7 https://trial.medpath.com/news/noraps-phase-2-trial-to-test-noradrenaline-reuptake-inhibitor-atomoxetine-in-psp 2024-10-02T23:11:12+00:00 weekly 0.7 https://trial.medpath.com/news/dcisionrt-biosignature-identifies-residual-recurrence-risk-in-her2-3-breast-cancer 2024-10-02T22:58:15+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-ind-for-respirx-inhalable-nicotine-replacement-therapy-pharmacy-times 2024-10-02T22:38:30+00:00 weekly 0.7 https://trial.medpath.com/news/three-outcome-designs-for-external-pilot-trials-with-progression-criteria 2024-10-02T22:34:40+00:00 weekly 0.7 https://trial.medpath.com/news/monogram-technologies-receives-fda-response-for-mbos-tka-system-stock-titan 2024-10-02T22:30:05+00:00 weekly 0.7 https://trial.medpath.com/news/myrtelle-s-canavan-disease-gene-therapy-raav-olig001-aspa-decreases-n 2024-10-02T22:16:51+00:00 weekly 0.7 https://trial.medpath.com/news/exploring-the-complexities-of-clinical-oncology-bowdoin-college 2024-10-02T22:11:24+00:00 weekly 0.7 https://trial.medpath.com/news/erleada-demonstrates-statistically-significant-and-clinically-meaningful-improvement-in-overall-survival-compared-to-enzalutamide-in-patients-with-metastatic-castration-sensitive-prostate-cancer 2024-10-02T22:10:17+00:00 weekly 0.7 https://trial.medpath.com/news/radiotherapy-vs-transoral-robotic-surgery-for-oropharyngeal-squamous-cell-carcinoma 2024-10-02T21:58:13+00:00 weekly 0.7 https://trial.medpath.com/news/aethlon-medical-expands-equity-incentive-plan-by-3-million-shares-investing-com-uk 2024-10-02T21:23:08+00:00 weekly 0.7 https://trial.medpath.com/news/september-2024-fda-roundup-key-decisions-drive-oncology-forward 2024-10-02T21:06:41+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-examines-standard-vs-extended-lymph-node-removal-for-muscle-invasive 2024-10-02T21:00:42+00:00 weekly 0.7 https://trial.medpath.com/news/safety-and-efficacy-assessment-of-fecal-microbiota-transplantation-as-an-adjunctive-nature 2024-10-02T20:46:33+00:00 weekly 0.7 https://trial.medpath.com/news/medulloblastoma-initiative-unveils-latest-impact-report-showcasing-breakthrough-fda 2024-10-02T20:34:23+00:00 weekly 0.7 https://trial.medpath.com/news/arcus-biosciences-announces-clinical-trial-collaboration-agreement-to-evaluate-yahoo-finance 2024-10-02T20:32:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-finalizes-q-a-guidance-on-electronic-records-in-clinical-trials-raps 2024-10-02T20:29:58+00:00 weekly 0.7 https://trial.medpath.com/news/acurx-reports-positive-trial-results-for-new-antibiotic-02-10-2024-kursiv-kz 2024-10-02T20:18:41+00:00 weekly 0.7 https://trial.medpath.com/news/biotechnology-company-launches-cancer-vaccine-trial-for-dogs-dvm360 2024-10-02T20:12:40+00:00 weekly 0.7 https://trial.medpath.com/news/tryptase-inhibitor-did-not-significantly-affect-time-to-asthma-exacerbation 2024-10-02T20:04:50+00:00 weekly 0.7 https://trial.medpath.com/news/rice-s-biotech-launch-pad-to-lead-commercialization-of-bioelectrical-implant-treatment-for 2024-10-02T19:55:48+00:00 weekly 0.7 https://trial.medpath.com/news/lecanemab-side-effects-potential-risks-in-cvd-patients-clinical-advisor 2024-10-02T19:12:01+00:00 weekly 0.7 https://trial.medpath.com/news/missouri-is-supporting-research-on-how-magic-mushrooms-can-treat-drug-addiction-with 2024-10-02T19:06:48+00:00 weekly 0.7 https://trial.medpath.com/news/recursion-gets-fda-approval-to-begin-phase-1-trials-of-ai-discovered-cancer-treatment 2024-10-02T18:54:18+00:00 weekly 0.7 https://trial.medpath.com/news/ninth-circuit-strengthens-fda-authority-to-enforce-drug-regs-against-certain-stem-cell-products 2024-10-02T18:39:10+00:00 weekly 0.7 https://trial.medpath.com/news/data-supports-approval-of-biosimilar-aflibercept-for-diabetic-macular-edema 2024-10-02T18:29:54+00:00 weekly 0.7 https://trial.medpath.com/news/the-drug-that-s-helping-the-world-quit-smoking-except-in-america 2024-10-02T18:00:50+00:00 weekly 0.7 https://trial.medpath.com/news/researchers-develop-insights-into-kras-mutations-in-pancreatic-cancers-medical-xpress 2024-10-02T17:23:46+00:00 weekly 0.7 https://trial.medpath.com/news/anixa-biosciences-seeks-protocol-change-to-enable-repeat-dosing-in-trial-for-ovarian 2024-10-02T17:18:14+00:00 weekly 0.7 https://trial.medpath.com/news/hido-technologies-awarded-phase-ii-sbir-grant-by-national-institute-on-aging-nia-for-prweb 2024-10-02T17:01:46+00:00 weekly 0.7 https://trial.medpath.com/news/biostem-technologies-initiates-br-ac-dfu-101-clinical-trial-globenewswire 2024-10-02T17:01:31+00:00 weekly 0.7 https://trial.medpath.com/news/emergex-t-cell-priming-vaccine-candidate-for-betacoronaviruses-selected-by-nih-niaid 2024-10-02T16:54:29+00:00 weekly 0.7 https://trial.medpath.com/news/anti-cancer-antibodies-may-aid-early-melanoma-detection-inside-precision-medicine 2024-10-02T16:46:21+00:00 weekly 0.7 https://trial.medpath.com/news/apalutamide-associated-with-improved-survival-vs-enzalutamide-in-mcspc-urology-times 2024-10-02T16:43:42+00:00 weekly 0.7 https://trial.medpath.com/news/decadine-demonstrates-therapeutic-potential-for-the-treatment-of-myelofibrosis 2024-10-02T16:16:47+00:00 weekly 0.7 https://trial.medpath.com/news/conformal-medical-kicks-off-left-atrial-appendage-occlusion-device-trial-massdevice 2024-10-02T16:16:30+00:00 weekly 0.7 https://trial.medpath.com/news/biointellisense-wins-fda-nod-for-biobutton-multi-patient-wearable-monitor-massdevice 2024-10-02T16:16:29+00:00 weekly 0.7 https://trial.medpath.com/news/molecular-and-functional-landscape-of-malignant-serous-effusions-for-precision-oncology 2024-10-02T15:38:01+00:00 weekly 0.7 https://trial.medpath.com/news/weight-loss-from-glp-1-drugs-not-as-robust-in-real-world-settings-forbes 2024-10-02T15:29:38+00:00 weekly 0.7 https://trial.medpath.com/news/masld-a-disease-in-flux-nature-reviews-gastroenterology-hepatology 2024-10-02T14:59:04+00:00 weekly 0.7 https://trial.medpath.com/news/exscientia-outline-robot-and-ai-use-in-drug-discovery-workflow-pharmaceutical-technology 2024-10-02T14:44:16+00:00 weekly 0.7 https://trial.medpath.com/news/dr-reddy-s-ties-up-with-gilead-to-manufacture-commercialise-hiv-drug-business-standard 2024-10-02T14:40:05+00:00 weekly 0.7 https://trial.medpath.com/news/us-fda-authorizes-launch-of-clinical-trial-to-support-new-treatment-development-for-progeria 2024-10-02T14:34:59+00:00 weekly 0.7 https://trial.medpath.com/news/ions-rare-neurology-disorder-candidate-gets-fda-s-fast-track-tag-barchart-com 2024-10-02T14:23:44+00:00 weekly 0.7 https://trial.medpath.com/news/safer-epilepsy-treatment-for-pregnant-women-with-drug-combo-neuroscience-news 2024-10-02T14:14:01+00:00 weekly 0.7 https://trial.medpath.com/news/onyda-xr-first-liquid-nonstimulant-for-adhd-now-available-in-us-drug-topics 2024-10-02T14:13:41+00:00 weekly 0.7 https://trial.medpath.com/news/lymphoplasmacytic-lymphoma-vaccine-leads-to-potential-clinical-benefit-as-early-intervention 2024-10-02T14:09:16+00:00 weekly 0.7 https://trial.medpath.com/news/with-115m-more-triveni-accelerates-immune-drug-work-biopharma-dive 2024-10-02T14:06:27+00:00 weekly 0.7 https://trial.medpath.com/news/alterity-therapeutics-raises-profile-with-multiple-data-presentations-at-the-international-biospace 2024-10-02T13:34:47+00:00 weekly 0.7 https://trial.medpath.com/news/adoptive-cell-therapy-clinical-trials-report-2024-trends 2024-10-02T13:31:15+00:00 weekly 0.7 https://trial.medpath.com/news/hepatology-month-in-review-september-2024-hcplive 2024-10-02T13:31:13+00:00 weekly 0.7 https://trial.medpath.com/news/jaguar-s-diarrhoea-drug-shows-benefit-in-phase-iii-breast-cancer-subgroup 2024-10-02T13:28:23+00:00 weekly 0.7 https://trial.medpath.com/news/alzecure-s-acd856-s-effects-to-be-presented-at-alzheimer-s-conference-pharmatimes 2024-10-02T13:27:01+00:00 weekly 0.7 https://trial.medpath.com/news/oryzon-genomics-fda-aligns-on-phase-iii-bpd-plans-edison-investment-research 2024-10-02T12:56:39+00:00 weekly 0.7 https://trial.medpath.com/news/kazia-therapeutics-announces-presentation-of-promising-phase-i-data-evaluating 2024-10-02T12:50:54+00:00 weekly 0.7 https://trial.medpath.com/news/bristol-myers-squibb-announces-positive-data-for-sotyktu-in-moderate-to-severe-psoriasis 2024-10-02T12:43:39+00:00 weekly 0.7 https://trial.medpath.com/news/novaliq-and-laboratoires-thea-announce-partnership-and-eu-approval-for-vevizye 2024-10-02T12:40:33+00:00 weekly 0.7 https://trial.medpath.com/news/volastra-therapeutics-granted-fda-fast-track-designation-for-novel-kif18a-inhibitor-in 2024-10-02T12:36:12+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-abionic-s-ivd-capsule-psp-for-the-early-detection-of-sepsis-biospace 2024-10-02T12:36:11+00:00 weekly 0.7 https://trial.medpath.com/news/pds-biotech-announces-36-month-overall-survival-rate-of-globenewswire 2024-10-02T12:22:10+00:00 weekly 0.7 https://trial.medpath.com/news/a-digital-intervention-for-cognitive-deficits-following-covid-19-a-randomized-clinical-trial 2024-10-02T12:15:30+00:00 weekly 0.7 https://trial.medpath.com/news/first-patient-dosed-in-phase-3-clinical-trial-of-ugn-103-a-next-generation-mitomycin 2024-10-02T12:06:15+00:00 weekly 0.7 https://trial.medpath.com/news/setpoint-medical-receives-fda-s-ide-approval-for-u-s-pilot-study-of-neuroimmune 2024-10-02T12:06:09+00:00 weekly 0.7 https://trial.medpath.com/news/genieus-genomics-announces-completion-of-phase-2-clinical-trial-enrollment-ein-news 2024-10-02T12:02:51+00:00 weekly 0.7 https://trial.medpath.com/news/the-influence-of-simultaneous-posterior-colporrhaphy-and-perineoplasty-on-the-efficiency 2024-10-02T11:34:25+00:00 weekly 0.7 https://trial.medpath.com/news/toleranzia-submits-a-clinical-trial-application-cta-for-the-drug-candidate-tol2-for-the-placera 2024-10-02T11:13:10+00:00 weekly 0.7 https://trial.medpath.com/news/ocugen-to-present-at-the-2024-cell-gene-meeting-on-the-mesa-globenewswire 2024-10-02T10:50:15+00:00 weekly 0.7 https://trial.medpath.com/news/amsel-medical-signs-7-45m-phase-iii-sbir-contract-yahoo-finance 2024-10-02T10:49:42+00:00 weekly 0.7 https://trial.medpath.com/news/genenta-secures-approval-for-innovative-trial-for-metastatic-renal-cell-cancer-stock-titan 2024-10-02T10:48:21+00:00 weekly 0.7 https://trial.medpath.com/news/one-in-three-americans-has-a-dysfunctional-metabolism-clinical-trial-suggests-intermittent 2024-10-02T10:22:56+00:00 weekly 0.7 https://trial.medpath.com/news/surmodics-receives-fda-510-k-clearance-for-pounce-xl-thrombectomy-system 2024-10-02T09:43:09+00:00 weekly 0.7 https://trial.medpath.com/news/fierce-names-insilico-medicine-as-one-of-its-fierce-50-honorees-of-2024-eurekalert 2024-10-02T09:25:26+00:00 weekly 0.7 https://trial.medpath.com/news/her2-directed-adcs-spread-like-wildfire-across-the-spectrum-of-solid-malignancies 2024-10-02T09:16:16+00:00 weekly 0.7 https://trial.medpath.com/news/can-flashing-lights-stall-alzheimer-s-what-the-science-shows-nature 2024-10-02T09:16:15+00:00 weekly 0.7 https://trial.medpath.com/news/brain-zap-treatment-could-get-arms-hands-moving-after-head-injury 2024-10-02T09:10:52+00:00 weekly 0.7 https://trial.medpath.com/news/coffee-water-soda-which-raise-your-odds-for-stroke 2024-10-02T09:10:30+00:00 weekly 0.7 https://trial.medpath.com/news/a-phenocopy-signature-of-tp53-loss-predicts-response-to-chemotherapy 2024-10-02T08:47:29+00:00 weekly 0.7 https://trial.medpath.com/news/spineguard-obtains-fda-clearance-for-commercial-release-of-its-psifguard-new-smart 2024-10-02T08:46:09+00:00 weekly 0.7 https://trial.medpath.com/news/jlk-s-ai-stroke-solution-receives-fda-approval-businesskorea 2024-10-02T08:43:41+00:00 weekly 0.7 https://trial.medpath.com/news/after-cassava-alzheimer-drug-fiasco-fda-must-protect-patients-stat-news 2024-10-02T08:39:02+00:00 weekly 0.7 https://trial.medpath.com/news/ensysce-biosciences-updates-shareholders-on-clinical-progress-and-financial-status 2024-10-02T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/terrapower-isotopes-brings-actinium-225-to-market 2024-10-02T07:57:10+00:00 weekly 0.7 https://trial.medpath.com/news/pbm-reform-urgently-needed-as-drug-pricing-crisis-deepens-industry-analysis-shows 2024-10-02T07:45:00+00:00 weekly 0.7 https://trial.medpath.com/news/allogeneic-t-cell-therapy-produces-efficacy-at-10-months-in-stage-iv-metastatic-nsclc 2024-10-02T07:12:04+00:00 weekly 0.7 https://trial.medpath.com/news/exact-therapeutics-to-present-at-the-bi-annual-contrast-media-research-cmr-symposium-2024 2024-10-02T06:42:25+00:00 weekly 0.7 https://trial.medpath.com/news/wuxi-apptec-predicts-shift-from-antibodies-to-peptides-in-radiopharmaceutical-development 2024-10-02T06:37:06+00:00 weekly 0.7 https://trial.medpath.com/news/halda-therapeutics-appoints-christian-schade-as-ceo-citybiz 2024-10-02T06:05:58+00:00 weekly 0.7 https://trial.medpath.com/news/scope-of-things-trial-planning-skews-conclusions-ai-diversity-help-news-of-the-month 2024-10-02T05:00:09+00:00 weekly 0.7 https://trial.medpath.com/news/phase-ii-basket-trial-of-dual-anti-ctla-4-and-anti-pd-1-blockade-in-rare-tumors 2024-10-02T04:18:41+00:00 weekly 0.7 https://trial.medpath.com/news/jazz-pharmaceuticals-inc-latest-stock-news-market-updates 2024-10-02T02:46:43+00:00 weekly 0.7 https://trial.medpath.com/news/merck-completes-acquisition-of-investigational-bispecific-antibody-therapy-from-curon 2024-10-02T02:28:44+00:00 weekly 0.7 https://trial.medpath.com/news/ai-and-community-based-trials-drive-145-increase-in-clinical-trial-engagement-promising-greater-diversity 2024-10-02T01:17:46+00:00 weekly 0.7 https://trial.medpath.com/news/avmf-stanton-foundation-offering-150000-research-grant 2024-10-02T01:06:46+00:00 weekly 0.7 https://trial.medpath.com/news/thryv-therapeutics-granted-fda-orphan-drug-designation-for-lqt-1213-in-long-qt 2024-10-02T01:01:04+00:00 weekly 0.7 https://trial.medpath.com/news/tnk-stroke-treatment-how-it-works-administration-and-more-medicalnewstoday 2024-10-02T00:44:10+00:00 weekly 0.7 https://trial.medpath.com/news/nearly-half-of-fda-authorized-ai-tools-may-provide-little-benefit-medical-economics 2024-10-02T00:27:05+00:00 weekly 0.7 https://trial.medpath.com/news/first-in-class-ar-degrader-shows-promise-in-castration-resistant-prostate-cancer-dana-rathkopf 2024-10-02T00:22:12+00:00 weekly 0.7 https://trial.medpath.com/news/roswell-park-radiation-oncologist-highlights-new-insights-on-single-fraction-radiation-for 2024-10-01T23:19:39+00:00 weekly 0.7 https://trial.medpath.com/news/ascendis-pharma-submits-fda-application-for-expanded-use-of-skytrofa-medwatch 2024-10-01T22:35:48+00:00 weekly 0.7 https://trial.medpath.com/news/astro-2024-combination-of-nivolumab-immunotherapy-with-radiation-therapy-and-urotoday 2024-10-01T22:27:41+00:00 weekly 0.7 https://trial.medpath.com/news/suicide-attempts-reduced-by-25-with-integrated-primary-care-intervention 2024-10-01T22:25:44+00:00 weekly 0.7 https://trial.medpath.com/news/maze-therapeutics-initiates-phase-1-first-in-human-trial-evaluating-mze782-as-a-potential 2024-10-01T22:17:08+00:00 weekly 0.7 https://trial.medpath.com/news/bms-986393-shows-first-in-class-potential-in-relapsed-refractory-multiple-myeloma 2024-10-01T21:31:54+00:00 weekly 0.7 https://trial.medpath.com/news/perimeter-announces-completion-of-patient-enrollment-in-pivotal-clinical-trial-evaluating 2024-10-01T20:25:04+00:00 weekly 0.7 https://trial.medpath.com/news/breast-cancer-patients-denied-precious-time-with-loved-ones-as-new-drug-korserdu-rejected-on-nhs 2024-10-01T20:05:18+00:00 weekly 0.7 https://trial.medpath.com/news/adaptive-radiotherapy-modality-appears-safe-feasible-in-high-grade-glioma 2024-10-01T19:33:41+00:00 weekly 0.7 https://trial.medpath.com/news/outrage-of-the-month-expanded-fda-approval-of-a-gene-therapy-for-muscular-dystrophy 2024-10-01T19:31:35+00:00 weekly 0.7 https://trial.medpath.com/news/eirion-therapeutics-announces-results-of-first-in-human-clinical-trial-evaluating-ready-to 2024-10-01T19:02:19+00:00 weekly 0.7 https://trial.medpath.com/news/ptc-therapeutics-announces-fda-acceptance-for-filing-of-nda-for-sepiapterin-for-pr-newswire 2024-10-01T19:01:49+00:00 weekly 0.7 https://trial.medpath.com/news/psilocybin-s-potentially-revolutionary-ability-to-treat-depression-hinges-on-fda-approval 2024-10-01T18:49:03+00:00 weekly 0.7 https://trial.medpath.com/news/invivyd-announces-u-s-fda-has-updated-the-pemgardatm-eua-fact-sheet-with-accurate 2024-10-01T18:01:10+00:00 weekly 0.7 https://trial.medpath.com/news/cancer-patients-who-experience-cognitive-decline-after-radiation-treatment-for-brain 2024-10-01T17:44:29+00:00 weekly 0.7 https://trial.medpath.com/news/ultrasound-method-linked-with-improved-survival-in-patients-with-crc-liver-metastases 2024-10-01T17:43:02+00:00 weekly 0.7 https://trial.medpath.com/news/pre-operative-prediction-of-bcr-free-survival-with-mrna-variables-in-prostate-cancer-plos-one 2024-10-01T17:40:45+00:00 weekly 0.7 https://trial.medpath.com/news/can-telehealth-help-patients-stick-with-buprenorphinie-for-opioid-addiction-uc-davis-health 2024-10-01T17:39:25+00:00 weekly 0.7 https://trial.medpath.com/news/gritstone-bio-reports-positive-interim-phase-2-data-investing-com 2024-10-01T17:26:35+00:00 weekly 0.7 https://trial.medpath.com/news/for-the-first-time-a-drug-developed-at-uwm-enters-fda-clinical-trials-letters-science 2024-10-01T17:15:12+00:00 weekly 0.7 https://trial.medpath.com/news/5-fda-decisions-to-watch-in-the-fourth-quarter-biopharma-dive 2024-10-01T17:06:27+00:00 weekly 0.7 https://trial.medpath.com/news/ember-imlunestrant-in-estrogen-receptor-positive-her2-negative-advanced-breast-cancer 2024-10-01T16:30:10+00:00 weekly 0.7 https://trial.medpath.com/news/acumen-and-lonza-expand-collaboration-for-early-alzheimer-s-drug 2024-10-01T16:17:53+00:00 weekly 0.7 https://trial.medpath.com/news/kailera-therapeutics-emerges-from-stealth-with-400m-for-obesity-drugs-biopharma-dive 2024-10-01T16:08:03+00:00 weekly 0.7 https://trial.medpath.com/news/repare-therapeutics-announces-phase-1-data-highlighting-camonsertib-in-combination 2024-10-01T16:03:10+00:00 weekly 0.7 https://trial.medpath.com/news/alzheimer-s-drug-lecanemab-ema-re-examining-marketing-authorisation-euractiv 2024-10-01T15:35:57+00:00 weekly 0.7 https://trial.medpath.com/news/glp-1-weight-loss-meds-could-interfere-with-endoscopy-colonoscopy 2024-10-01T15:10:35+00:00 weekly 0.7 https://trial.medpath.com/news/researchers-identify-new-therapeutic-approach-to-preventing-cancer-from-spreading-to-the-brain 2024-10-01T15:05:56+00:00 weekly 0.7 https://trial.medpath.com/news/is-gene-therapy-the-next-big-step-in-vision-loss-treatment-medicalnewstoday 2024-10-01T15:03:46+00:00 weekly 0.7 https://trial.medpath.com/news/dr-reddy-s-receives-positive-chmp-opinion-from-european-medicines-agency-for-its-bizz-buzz 2024-10-01T14:50:14+00:00 weekly 0.7 https://trial.medpath.com/news/ron-renaud-s-new-obesity-biotech-kailera-has-400m-to-go-straight-to-phase-3 2024-10-01T14:43:43+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trials-at-children-s-of-alabama-help-find-the-best-treatments-for-children-with-cancer 2024-10-01T14:42:18+00:00 weekly 0.7 https://trial.medpath.com/news/drones-and-biotechs-are-moving-this-morning-raging-bull 2024-10-01T14:39:05+00:00 weekly 0.7 https://trial.medpath.com/news/mpox-declared-international-public-health-emergency-as-cases-continue-to-rise 2024-10-01T14:37:32+00:00 weekly 0.7 https://trial.medpath.com/news/targeted-treatment-provides-orr-and-pfs-benefit-in-pretreated-metastatic-solid-tumors 2024-10-01T14:29:49+00:00 weekly 0.7 https://trial.medpath.com/news/rationale-and-design-of-the-study-to-investigate-the-metabolic-action-of-imeglimin-on 2024-10-01T14:06:49+00:00 weekly 0.7 https://trial.medpath.com/news/teva-pharma-launches-octreotide-acetate-for-injectable-suspension-quick-facts 2024-10-01T14:04:56+00:00 weekly 0.7 https://trial.medpath.com/news/ascelia-pharma-s-primary-results-from-phase-iii-study-to-be-presented-at-rsna-conference 2024-10-01T14:01:58+00:00 weekly 0.7 https://trial.medpath.com/news/denifanstat-receives-breakthrough-therapy-designation-for-noncirrhotic-mash-hcplive 2024-10-01T13:56:16+00:00 weekly 0.7 https://trial.medpath.com/news/sermonix-pharmaceuticals-lasofoxifene-demonstrates-anti-estrogen-therapy-increases 2024-10-01T13:32:55+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-aims-to-expand-weight-loss-drug-trials-to-those-at-risk-not-just-overweight 2024-10-01T13:13:38+00:00 weekly 0.7 https://trial.medpath.com/news/mechanism-behind-ulixacaltamide-to-treat-essential-tremor-marcio-souza-neurologylive 2024-10-01T12:49:47+00:00 weekly 0.7 https://trial.medpath.com/news/barinthus-bio-completes-enrollment-for-phase-2b-hbv003-globenewswire 2024-10-01T12:11:30+00:00 weekly 0.7 https://trial.medpath.com/news/bioatla-announces-upcoming-oral-presentation-at-the-society-globenewswire 2024-10-01T12:03:14+00:00 weekly 0.7 https://trial.medpath.com/news/igm-biosciences-shifts-focus-to-autoimmune-disease-research-amid-staff-layoffs 2024-10-01T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/chemomab-therapeutics-to-present-at-october-2024-investor-conferences-biospace 2024-10-01T11:55:02+00:00 weekly 0.7 https://trial.medpath.com/news/register-certain-tests-for-phase-3-of-the-dex-z-codes-uhcprovider-com 2024-10-01T11:55:00+00:00 weekly 0.7 https://trial.medpath.com/news/cybin-expands-clinical-team-to-support-cyb003-phase-3-program-morningstar 2024-10-01T11:41:25+00:00 weekly 0.7 https://trial.medpath.com/news/aurobindo-pharma-receives-us-fda-approval-for-an-antibiotics-tablet-ndtv-profit 2024-10-01T11:23:52+00:00 weekly 0.7 https://trial.medpath.com/news/polypid-enrolls-last-patient-for-planned-unblinded-interim-analysis-in-shield-ii-tipranks 2024-10-01T11:22:52+00:00 weekly 0.7 https://trial.medpath.com/news/zilganersen-granted-u-s-fda-fast-track-designation-for-people-living-with-alexander-disease 2024-10-01T11:14:01+00:00 weekly 0.7 https://trial.medpath.com/news/edap-announces-first-patients-treated-in-phase-i-ii-study-evaluating-focal-one-robotic 2024-10-01T11:12:40+00:00 weekly 0.7 https://trial.medpath.com/news/cytosorbents-submits-drugsorb-atr-marketing-application-to-globenewswire 2024-10-01T11:05:07+00:00 weekly 0.7 https://trial.medpath.com/news/shattuck-labs-provides-company-update-and-announces-sl-325-globenewswire 2024-10-01T10:33:58+00:00 weekly 0.7 https://trial.medpath.com/news/spima-therapeutics-starts-with-global-licence-agreement-european-biotechnology 2024-10-01T10:26:31+00:00 weekly 0.7 https://trial.medpath.com/news/cel-sci-selects-ergomed-as-cro-as-it-gears-up-for-confirmatory-fda-registration-study 2024-10-01T10:25:07+00:00 weekly 0.7 https://trial.medpath.com/news/a-review-of-recent-clinical-trials-to-evaluate-disease-modifying-therapies-in-the-treatment-frontiers 2024-10-01T09:59:33+00:00 weekly 0.7 https://trial.medpath.com/news/spago-nanomedical-in-new-phase-with-full-focus-on-the-tumorad-program 2024-10-01T09:51:02+00:00 weekly 0.7 https://trial.medpath.com/news/sacituzumab-govitecan-in-hr-her2-metastatic-breast-cancer-the-randomized-phase-3 2024-10-01T09:50:19+00:00 weekly 0.7 https://trial.medpath.com/news/kezar-life-sciences-suspends-subject-enrolment-in-trial-of-lupus-nephritis-drug 2024-10-01T09:46:08+00:00 weekly 0.7 https://trial.medpath.com/news/black-white-cancer-patients-now-benefit-equally-from-cord-blood-therapy 2024-10-01T09:10:57+00:00 weekly 0.7 https://trial.medpath.com/news/covid-shot-lowers-your-odds-for-covid-linked-heart-trouble 2024-10-01T09:10:14+00:00 weekly 0.7 https://trial.medpath.com/news/arun-upadhyay-phd-on-results-from-ird-gene-therapy-ocu400-s-phase-1-2-trial 2024-10-01T08:47:41+00:00 weekly 0.7 https://trial.medpath.com/news/study-links-conversion-practices-to-increased-mental-health-risks-in-lgbtq-adults 2024-10-01T08:13:07+00:00 weekly 0.7 https://trial.medpath.com/news/incannex-healthcare-inc-reports-fiscal-full-year-2024-financial-results-and-business-updates 2024-10-01T08:02:16+00:00 weekly 0.7 https://trial.medpath.com/news/sequana-medical-announces-h1-2024-results-and-provides-business-update-biospace 2024-10-01T07:58:45+00:00 weekly 0.7 https://trial.medpath.com/news/cartherics-raises-over-15-million-in-oversubscribed-private-financing-round-to-advance 2024-10-01T07:58:44+00:00 weekly 0.7 https://trial.medpath.com/news/drug-shortages-in-australia-highlight-critical-need-to-include-pregnant-women-in-clinical-trials 2024-10-01T06:26:45+00:00 weekly 0.7 https://trial.medpath.com/news/survey-reveals-low-intent-for-respiratory-vaccinations-among-us-adults-for-2024-2025-season 2024-10-01T05:08:00+00:00 weekly 0.7 https://trial.medpath.com/news/study-highlights-promising-new-treatment-option-for-patients-with-treatment-resistant 2024-10-01T05:05:09+00:00 weekly 0.7 https://trial.medpath.com/news/key-medical-conferences-set-to-shape-biopharma-industry-in-2025 2024-10-01T04:34:00+00:00 weekly 0.7 https://trial.medpath.com/news/talapro-2-analysis-talazoparib-enzalutamide-combo-in-pretreated-mcrpc-neeraj-agarwal 2024-10-01T04:25:33+00:00 weekly 0.7 https://trial.medpath.com/news/avera-medical-minute-avera-offers-phase-1-clinical-trials-for-cancer-patients-dakota-news-now 2024-10-01T03:40:27+00:00 weekly 0.7 https://trial.medpath.com/news/msd-terminates-phase-ii-trials-for-alzheimer-s-drug-due-to-liver-toxicity-msn 2024-10-01T02:53:22+00:00 weekly 0.7 https://trial.medpath.com/news/zilganersen-granted-u-s-fda-fast-track-designation-for-people-living-with-alexander-disease 2024-10-01T02:10:53+00:00 weekly 0.7 https://trial.medpath.com/news/llms-set-to-transform-clinical-trial-management-through-enhanced-irt-systems 2024-10-01T00:49:02+00:00 weekly 0.7 https://trial.medpath.com/news/sapience-therapeutics-enrolls-first-patient-in-phase-2-study-of-st316 2024-10-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/doxycycline-prophylaxis-for-the-prevention-of-sexually 2024-10-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a-phase-i-study-of-iag933-in-patients-with-advanced 2024-10-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sonrotoclax-dexamethasone-combo-is-tolerable-generates-deep-responses-in-t-11-14-r 2024-09-30T23:48:59+00:00 weekly 0.7 https://trial.medpath.com/news/clinuvel-files-canadian-new-drug-submission-for-scenesse-r-in-epp-globenewswire 2024-09-30T23:11:21+00:00 weekly 0.7 https://trial.medpath.com/news/hypofractionated-rt-after-mastectomy-is-noninferior-to-soc-in-breast-cancer 2024-09-30T23:11:02+00:00 weekly 0.7 https://trial.medpath.com/news/redhill-announces-new-u-s-coronavirus-patent-for-opaganib-valid-through-2041 2024-09-30T23:01:08+00:00 weekly 0.7 https://trial.medpath.com/news/buy-recommendation-for-bridgebio-pharma-amidst-promising-drug-trials-and-upcoming 2024-09-30T22:31:35+00:00 weekly 0.7 https://trial.medpath.com/news/legend-biotech-reiterates-stock-target-overweight-on-phase-iii-data-investing-com 2024-09-30T22:14:46+00:00 weekly 0.7 https://trial.medpath.com/news/struggling-to-find-an-effective-depression-treatment-the-reporter-uab 2024-09-30T22:10:57+00:00 weekly 0.7 https://trial.medpath.com/news/roche-turns-to-a-startup-in-search-for-new-breast-cancer-drugs-biopharma-dive 2024-09-30T22:06:11+00:00 weekly 0.7 https://trial.medpath.com/news/america-s-nobel-goes-to-a-power-couple-who-made-a-startling-discovery-about-hiv 2024-09-30T22:05:20+00:00 weekly 0.7 https://trial.medpath.com/news/university-awarded-12-million-to-further-develop-opioid-use-disorder-drug 2024-09-30T21:51:21+00:00 weekly 0.7 https://trial.medpath.com/news/neurocrine-biosciences-s-crinecerfont-is-set-to-transform-the-congenital-adrenal-pr-newswire 2024-09-30T21:38:25+00:00 weekly 0.7 https://trial.medpath.com/news/ucsf-radiation-oncologist-honored-for-prostate-cancer-care-and-research-newswise 2024-09-30T21:18:25+00:00 weekly 0.7 https://trial.medpath.com/news/trial-supports-radiotherapy-and-cisplatin-remaining-as-the-standard-of-care-for-p16 2024-09-30T21:16:48+00:00 weekly 0.7 https://trial.medpath.com/news/triplet-vs-soc-explored-in-metastatic-prostate-cancer-targeted-oncology 2024-09-30T21:06:03+00:00 weekly 0.7 https://trial.medpath.com/news/women-in-medicine-month-celebrating-women-advancing-radiology 2024-09-30T21:04:12+00:00 weekly 0.7 https://trial.medpath.com/news/study-time-restricted-eating-may-improve-health-of-adults-with-metabolic-syndrome 2024-09-30T21:00:19+00:00 weekly 0.7 https://trial.medpath.com/news/novel-pet-imaging-agent-earns-fast-track-status-for-psma-prostate-cancer 2024-09-30T20:24:45+00:00 weekly 0.7 https://trial.medpath.com/news/merus-announces-first-patient-dosed-in-liger-hn1-a-phase-3-trial-evaluating 2024-09-30T20:16:13+00:00 weekly 0.7 https://trial.medpath.com/news/standard-chemoradiation-outperforms-de-intensified-treatments-in-hpv-associated-news-medical 2024-09-30T19:35:39+00:00 weekly 0.7 https://trial.medpath.com/news/rheumatoid-arthritis-study-ids-macrophages-that-could-hasten-diagnosis-treatment 2024-09-30T19:26:26+00:00 weekly 0.7 https://trial.medpath.com/news/outpatient-car-t-therapy-shows-promise-for-treating-lymphoma-patients-news-medical 2024-09-30T19:19:29+00:00 weekly 0.7 https://trial.medpath.com/news/phase-3-real-world-data-show-deucravacitinib-efficacious-for-scalp-overall-psoriasis 2024-09-30T19:03:07+00:00 weekly 0.7 https://trial.medpath.com/news/route-66-spore-grant-to-study-uterine-cancers-unm-health-sciences-center 2024-09-30T18:52:05+00:00 weekly 0.7 https://trial.medpath.com/news/bristol-myers-beats-6-4-billion-lawsuit-over-delayed-cancer-drug-the-mighty-790-kfgo 2024-09-30T18:43:39+00:00 weekly 0.7 https://trial.medpath.com/news/pi-cardia-receives-fda-market-clearance-for-shortcuttm-biospace 2024-09-30T18:33:19+00:00 weekly 0.7 https://trial.medpath.com/news/walden-biosciences-fully-enrolls-first-cohort-in-phase-2-basket-study-of-wal0921-in-biospace 2024-09-30T18:32:57+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-efficacy-of-endostar-continuous-infusion-combined-with-concurrent-frontiers 2024-09-30T18:01:12+00:00 weekly 0.7 https://trial.medpath.com/news/from-the-esmo-congress-2024-nature-reviews-clinical-oncology 2024-09-30T17:52:31+00:00 weekly 0.7 https://trial.medpath.com/news/astro-2024-quality-of-life-in-patients-enrolled-in-a-randomized-clinical-trial-evaluating 2024-09-30T17:28:28+00:00 weekly 0.7 https://trial.medpath.com/news/2-year-study-affirms-bimekizumab-s-efficacy-in-hidradenitis-suppurativa 2024-09-30T17:21:18+00:00 weekly 0.7 https://trial.medpath.com/news/kras-inhibitors-market-new-treatments-are-set-to-change-cancer-care-delveinsight 2024-09-30T17:16:56+00:00 weekly 0.7 https://trial.medpath.com/news/exploiting-the-role-of-csf-nfl-chit1-and-mir-181b-as-potential-diagnostic-and-prognostic 2024-09-30T17:14:39+00:00 weekly 0.7 https://trial.medpath.com/news/ocuphire-pharma-releases-results-from-mira-2-and-mira-3-clinical-trials-for-phentolamine 2024-09-30T17:01:35+00:00 weekly 0.7 https://trial.medpath.com/news/biopharma-partnering-monthly-update-august-2024-taylor-wessing 2024-09-30T16:55:53+00:00 weekly 0.7 https://trial.medpath.com/news/migraine-drug-could-help-prevent-the-overuse-of-painkillers-miriam-stoppard-the-mirror 2024-09-30T16:47:13+00:00 weekly 0.7 https://trial.medpath.com/news/a-multi-center-randomized-double-blind-sham-stimulation-controlled-study-of-transcranial 2024-09-30T16:39:29+00:00 weekly 0.7 https://trial.medpath.com/news/prescribing-antipsychotics-in-patients-with-dementia-what-clinicians-should-know 2024-09-30T16:38:38+00:00 weekly 0.7 https://trial.medpath.com/news/updated-findings-with-belzutifan-in-von-hippel-lindau-disease-associated-cns 2024-09-30T16:22:34+00:00 weekly 0.7 https://trial.medpath.com/news/astro-2024-bladder-preservation-a-modern-choice-for-patients-urotoday 2024-09-30T16:14:18+00:00 weekly 0.7 https://trial.medpath.com/news/nrx-100-ketamine-reaches-stability-milestone-contract-pharma 2024-09-30T16:08:41+00:00 weekly 0.7 https://trial.medpath.com/news/astro-2024-strategies-and-evidence-for-sabr-in-rcc-urotoday 2024-09-30T15:57:36+00:00 weekly 0.7 https://trial.medpath.com/news/screening-for-helicobacter-pylori-to-prevent-gastric-cancer-a-pragmatic-randomized-clinical-trial 2024-09-30T15:56:01+00:00 weekly 0.7 https://trial.medpath.com/news/lanifibranor-may-promote-liver-gains-seen-in-phase-3-mash-trial 2024-09-30T15:50:34+00:00 weekly 0.7 https://trial.medpath.com/news/nih-fast-track-grant-for-novel-therapeutic-to-treat-glioblastoma-awarded-to-rosalind 2024-09-30T15:47:32+00:00 weekly 0.7 https://trial.medpath.com/news/mytomorrows-and-curelgmd2i-partnership-to-improve-access-to-clinical-trials-for-limb 2024-09-30T15:43:24+00:00 weekly 0.7 https://trial.medpath.com/news/siemens-healthineers-receives-fda-premarket-approval-for-3d-portion-of-mammography-system 2024-09-30T15:33:20+00:00 weekly 0.7 https://trial.medpath.com/news/opinion-goal-is-to-reverse-paralysis-if-washington-doesn-t-get-in-way-hartford-courant 2024-09-30T15:30:16+00:00 weekly 0.7 https://trial.medpath.com/news/sage-therapeutics-swot-analysis-cns-drug-maker-s-stock-faces-pipeline-hurdles 2024-09-30T15:18:24+00:00 weekly 0.7 https://trial.medpath.com/news/tumor-hypoxia-on-18f-fluoromisonidazole-positron-emission-tomography-and-distant 2024-09-30T15:18:23+00:00 weekly 0.7 https://trial.medpath.com/news/positive-phase-2a-data-suggest-disease-modifying-potential-of-cnp-104-in-pbc-hcplive 2024-09-30T15:13:41+00:00 weekly 0.7 https://trial.medpath.com/news/key-reasons-behind-surge-in-semaglutide-usage-european-pharmaceutical-manufacturer 2024-09-30T15:05:42+00:00 weekly 0.7 https://trial.medpath.com/news/neoadjuvant-therapy-trumps-surgery-in-nsclc-debate-cancer-network 2024-09-30T14:52:51+00:00 weekly 0.7 https://trial.medpath.com/news/uc-cancer-center-experts-present-research-at-astro-2024-university-of-cincinnati 2024-09-30T14:52:50+00:00 weekly 0.7 https://trial.medpath.com/news/a-standing-platform-for-cancer-drug-development-using-ctdna-based-evidence-of-recurrence-nature 2024-09-30T14:50:23+00:00 weekly 0.7 https://trial.medpath.com/news/arcturus-covid-19-vaccine-triggers-enhanced-immune-response 2024-09-30T14:49:25+00:00 weekly 0.7 https://trial.medpath.com/news/tenax-therapeutics-inc-initiation-of-research-coverage-william-blair 2024-09-30T14:43:11+00:00 weekly 0.7 https://trial.medpath.com/news/the-evolving-treatment-landscape-for-alzheimer-s-technology-networks 2024-09-30T14:42:20+00:00 weekly 0.7 https://trial.medpath.com/news/zydus-life-shares-gain-1-today-after-us-fda-approves-cancer-drug-worth-870-million 2024-09-30T14:13:37+00:00 weekly 0.7 https://trial.medpath.com/news/shorter-course-of-breast-cancer-radiation-won-t-affect-breast-reconstruction 2024-09-30T14:09:39+00:00 weekly 0.7 https://trial.medpath.com/news/trial-shows-timing-matters-when-adding-immunotherapy-to-chemoradiation-for-limited-stage 2024-09-30T14:08:31+00:00 weekly 0.7 https://trial.medpath.com/news/memed-s-diagnostic-reduces-antibiotic-overuse-in-us-trial-inside-precision-medicine 2024-09-30T13:56:10+00:00 weekly 0.7 https://trial.medpath.com/news/september-30-2024-new-guide-from-nih-collaboratory-promotes-health-equity-in 2024-09-30T13:47:02+00:00 weekly 0.7 https://trial.medpath.com/news/ascendis-pharma-announces-submission-of-supplemental-biologics-license-application-to 2024-09-30T13:34:49+00:00 weekly 0.7 https://trial.medpath.com/news/vaping-addiction-drug-developer-achieve-to-sell-up-to-50-million-of-stock-kursiv-kz 2024-09-30T13:33:20+00:00 weekly 0.7 https://trial.medpath.com/news/bay-area-surfer-scientologist-and-billionaire-is-tackling-one-of-medicine-s-toughest-problems 2024-09-30T13:19:57+00:00 weekly 0.7 https://trial.medpath.com/news/accelerate-diagnostics-announces-fda-clearance-of-its-accelerate-arctm-system 2024-09-30T13:19:45+00:00 weekly 0.7 https://trial.medpath.com/news/catching-up-with-synchron-s-tom-oxley-on-the-path-to-a-pivotal-trial 2024-09-30T13:16:31+00:00 weekly 0.7 https://trial.medpath.com/news/study-examining-use-of-nalmefene-hci-injection-for-opioid-overdose-reversal-in 2024-09-30T13:13:35+00:00 weekly 0.7 https://trial.medpath.com/news/bioai-arbele-partner-to-advance-predictive-ai-models-in-oncology-clinical-trials 2024-09-30T13:11:17+00:00 weekly 0.7 https://trial.medpath.com/news/penn-state-college-of-medicine-beat-childhood-cancer-research-consortium-and-four 2024-09-30T13:10:05+00:00 weekly 0.7 https://trial.medpath.com/news/madrigal-pharmaceuticals-announces-publication-of-positive-health-related-quality-of-life 2024-09-30T13:05:42+00:00 weekly 0.7 https://trial.medpath.com/news/inmune-bio-inc-completes-enrollment-for-phase-2-trial-in-early-alzheimer-s-disease 2024-09-30T13:05:41+00:00 weekly 0.7 https://trial.medpath.com/news/could-we-prevent-asthma-in-young-allergic-children-boston-children-s-answers 2024-09-30T13:05:12+00:00 weekly 0.7 https://trial.medpath.com/news/medicinova-to-support-nih-funded-expanded-access-clinical-globenewswire 2024-09-30T13:03:20+00:00 weekly 0.7 https://trial.medpath.com/news/mitsubishi-tanabe-pharma-america-presents-open-label-extension-outcomes-and-pr-newswire 2024-09-30T13:02:41+00:00 weekly 0.7 https://trial.medpath.com/news/nanoviricides-prepares-for-phase-ii-trials-for-antiviral-nv-387-nyse-a-nnvc 2024-09-30T13:01:37+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-in-the-fight-against-superbacteria-by-a-hungarian-research-team 2024-09-30T12:47:42+00:00 weekly 0.7 https://trial.medpath.com/news/advancing-clinical-basic-clinical-research-exploring-novel-immunotargets-for-ovarian-cancer 2024-09-30T12:45:30+00:00 weekly 0.7 https://trial.medpath.com/news/altimmune-completes-enrollment-in-phase-2b-impact-trial-of-pemvidutide-in-metabolic 2024-09-30T12:41:42+00:00 weekly 0.7 https://trial.medpath.com/news/windtree-announces-positive-phase-2b-topline-clinical-globenewswire 2024-09-30T12:36:30+00:00 weekly 0.7 https://trial.medpath.com/news/new-3-year-skeletal-dynamics-data-for-adults-with-hypoparathyroidism-treated-with-stock-titan 2024-09-30T12:34:52+00:00 weekly 0.7 https://trial.medpath.com/news/nervgen-pharma-provides-update-on-phase-1b-2a-clinical-trial-of-nvg-291-in-spinal-cord-injury 2024-09-30T12:34:47+00:00 weekly 0.7 https://trial.medpath.com/news/aeon-biopharma-announces-positive-outcome-from-fda-biosimilar-advisory-meeting 2024-09-30T12:22:50+00:00 weekly 0.7 https://trial.medpath.com/news/perfluorohexyloctane-ophthalmic-solution-for-dry-eye-disease-pooled-analysis-of-two-phase 2024-09-30T12:18:17+00:00 weekly 0.7 https://trial.medpath.com/news/precision-biosciences-submits-first-clinical-trial-applications-to-initiate-phase-1-trial-biospace 2024-09-30T12:17:38+00:00 weekly 0.7 https://trial.medpath.com/news/the-targeted-pulse-nkt2152-sparks-excitement-in-rcc-amivantamab-chemotherapy 2024-09-30T12:17:00+00:00 weekly 0.7 https://trial.medpath.com/news/adaptive-research-announces-it-has-begun-enrolling-patients-in-aribio-s-phase-3-polaris 2024-09-30T12:16:17+00:00 weekly 0.7 https://trial.medpath.com/news/calidi-biotherapeutics-announces-fda-clearance-of-the-globenewswire 2024-09-30T12:14:32+00:00 weekly 0.7 https://trial.medpath.com/news/neurobo-pharmaceuticals-announces-positive-top-line-data-from-the-sad-part-1-of-its 2024-09-30T12:04:36+00:00 weekly 0.7 https://trial.medpath.com/news/family-heart-foundation-launches-free-at-home-lipid-screening-program-to-combat-cardiovascular-disease 2024-09-30T12:00:41+00:00 weekly 0.7 https://trial.medpath.com/news/dana-farber-cancer-institute-raises-more-than-2-billion-in-record-breaking-fundraising 2024-09-30T11:43:22+00:00 weekly 0.7 https://trial.medpath.com/news/geneditbio-secures-strategic-investment-from-gobi-partners-gba-to-accelerate 2024-09-30T11:42:35+00:00 weekly 0.7 https://trial.medpath.com/news/bridgebio-completes-enrollment-of-fortify-phase-3-globenewswire 2024-09-30T11:33:37+00:00 weekly 0.7 https://trial.medpath.com/news/biohaven-initiates-pivotal-trial-of-novel-investigational-drug-for-treatment-of-migraine 2024-09-30T11:32:34+00:00 weekly 0.7 https://trial.medpath.com/news/national-institutes-of-health-study-finds-no-reliable-biomarkers-exist-for-long-covid 2024-09-30T11:29:08+00:00 weekly 0.7 https://trial.medpath.com/news/moderna-announces-first-participant-dosed-in-pivotal-phase-3-trial-of-investigational 2024-09-30T11:17:12+00:00 weekly 0.7 https://trial.medpath.com/news/2-minute-medicine-rewind-september-30-2024 2024-09-30T11:10:13+00:00 weekly 0.7 https://trial.medpath.com/news/biotech-stocks-facing-fda-decision-in-october-2024-rttnews 2024-09-30T11:05:21+00:00 weekly 0.7 https://trial.medpath.com/news/tonix-pharmaceuticals-announces-participation-in-endpoints-globenewswire 2024-09-30T11:01:41+00:00 weekly 0.7 https://trial.medpath.com/news/self-management-support-program-delivered-in-the-sub-acute-phase-after-traumatic-injury 2024-09-30T10:39:05+00:00 weekly 0.7 https://trial.medpath.com/news/nanoviricides-inc-has-filed-its-annual-report-broad-spectrum-antiviral-nv-387-stock-titan 2024-09-30T10:35:48+00:00 weekly 0.7 https://trial.medpath.com/news/primary-endpoint-met-in-phase-3-comparative-clinical-study-of-perjeta-r-pertuzumab 2024-09-30T10:18:55+00:00 weekly 0.7 https://trial.medpath.com/news/grunenthal-appoints-dr-jan-adams-as-chief-commercial-officer 2024-09-30T10:14:20+00:00 weekly 0.7 https://trial.medpath.com/news/pharmaust-limited-issues-new-shares-advances-als-treatment-tipranks-com 2024-09-30T09:34:58+00:00 weekly 0.7 https://trial.medpath.com/news/european-commission-approves-yuvanci-r-single-tablet-globenewswire 2024-09-30T09:16:31+00:00 weekly 0.7 https://trial.medpath.com/news/synthetic-thc-may-calm-agitation-in-alzheimer-s-patients 2024-09-30T09:09:56+00:00 weekly 0.7 https://trial.medpath.com/news/role-of-the-screening-with-coronary-computed-tomography-angiography-on-lipid-trials-journal 2024-09-30T08:34:37+00:00 weekly 0.7 https://trial.medpath.com/news/a-decade-of-pd-1-inhibitors-keytruda-and-opdivo-transform-global-cancer-treatment-landscape 2024-09-30T07:59:04+00:00 weekly 0.7 https://trial.medpath.com/news/medicines-regulators-weigh-hope-and-hype-with-new-alzheimer-s-drugs-swissinfo 2024-09-30T07:47:19+00:00 weekly 0.7 https://trial.medpath.com/news/doer-biologics-announces-first-patient-dosed-in-phase-2-study-of-dr10624-for-treatment 2024-09-30T07:19:07+00:00 weekly 0.7 https://trial.medpath.com/news/sifi-announces-allowance-of-patent-on-polihexanide-for-europe-and-commercial-launch-of 2024-09-30T07:01:03+00:00 weekly 0.7 https://trial.medpath.com/news/identifying-biomarkers-for-treatment-of-uveal-melanoma-by-t-cell-engager-using-a-qsp-model 2024-09-30T06:37:57+00:00 weekly 0.7 https://trial.medpath.com/news/ai-solutions-show-promise-in-combating-pharmacist-burnout-and-enhancing-patient-care 2024-09-30T06:36:29+00:00 weekly 0.7 https://trial.medpath.com/news/modalis-therapeutics-fda-grants-rare-pediatric-disease-designation-to-mdl-101-for-the 2024-09-30T06:24:27+00:00 weekly 0.7 https://trial.medpath.com/news/modalis-therapeutics-fda-grants-rare-pediatric-disease-designation-to-mdl-101-for-the 2024-09-30T06:21:47+00:00 weekly 0.7 https://trial.medpath.com/news/pharmacokinetics-and-pharmacogenomics-of-ribociclib-in-black-patients-with-metastatic 2024-09-30T06:16:25+00:00 weekly 0.7 https://trial.medpath.com/news/photocure-partner-asieris-unveils-cevira-apl-1702-phase-iii-subgroup-analysis-by-age 2024-09-30T06:05:07+00:00 weekly 0.7 https://trial.medpath.com/news/verona-pharma-to-present-six-analyses-of-the-phase-3-enhance-studies-in-copd-at-chest-2024 2024-09-30T06:03:10+00:00 weekly 0.7 https://trial.medpath.com/news/lexaria-receives-independent-review-board-approval-to-begin-human-pilot-study-3 2024-09-30T06:03:09+00:00 weekly 0.7 https://trial.medpath.com/news/cinclus-pharma-completes-imp-manufacturing-for-phase-iii-marketscreener 2024-09-30T05:56:24+00:00 weekly 0.7 https://trial.medpath.com/news/akeso-s-cadonilimab-receives-second-indication-approval-from-nmpa-for-first-line 2024-09-30T05:48:12+00:00 weekly 0.7 https://trial.medpath.com/news/veteran-tennessee-pharmacist-reflects-on-45-years-of-community-service-and-industry-evolution 2024-09-30T05:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/experts-highlight-critical-treatment-gaps-in-metastatic-colorectal-cancer-management 2024-09-30T05:00:50+00:00 weekly 0.7 https://trial.medpath.com/news/closer-to-us-commercialisation-ebr-achieves-major-fda-milestone-stockhead 2024-09-30T05:00:33+00:00 weekly 0.7 https://trial.medpath.com/news/ai-revolutionizes-healthcare-economics-transforming-clinical-trials-and-value-assessment 2024-09-30T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-action-alert-biofrontera-bms-and-zealand-biospace 2024-09-30T04:21:48+00:00 weekly 0.7 https://trial.medpath.com/news/jeil-pharm-launches-jaqbo-its-1st-in-house-drug-in-korea-s-1-billion-peptic-ulcer-market 2024-09-30T03:57:24+00:00 weekly 0.7 https://trial.medpath.com/news/duke-nus-study-proposes-new-heart-failure-treatment-targeting-abnormal-hormone-activity 2024-09-30T03:14:56+00:00 weekly 0.7 https://trial.medpath.com/news/percheron-therapeutics-completes-toxicology-study-for-avicursen-ahead-of-us-fda-discussions 2024-09-30T02:42:28+00:00 weekly 0.7 https://trial.medpath.com/news/valerio-therapeutics-expands-antibody-development-capabilities-with-emglev-therapeutics-acquisition 2024-09-30T02:38:12+00:00 weekly 0.7 https://trial.medpath.com/news/up-manila-researchers-unveil-promising-ampalaya-tablet-for-type-2-diabetes 2024-09-30T02:07:59+00:00 weekly 0.7 https://trial.medpath.com/news/mesoblast-to-raise-50m-from-top-shareholder-for-product-launch-capital-brief 2024-09-30T00:58:56+00:00 weekly 0.7 https://trial.medpath.com/news/cutia-therapeutics-completes-phase-ii-trial-tipranks-com 2024-09-30T00:11:13+00:00 weekly 0.7 https://trial.medpath.com/news/medidata-clinches-two-excellence-awards-for-innovative-clinical-trial-solutions 2024-09-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/irlab-completes-patient-enrollment-in-phase-iib-study-of-pirepemat-for-parkinson-s-disease 2024-09-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/merus-announces-fda-approval-of-bizengri-r 2024-09-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/histone-deacetylase-inhibition-enhances-extracellular-vesicles-from-muscle-to-promote 2024-09-29T23:48:16+00:00 weekly 0.7 https://trial.medpath.com/news/initial-results-of-a-phase-2-trial-of-stereotactic-body-radiation-therapy-hormone-androgen 2024-09-29T23:27:21+00:00 weekly 0.7 https://trial.medpath.com/news/bladder-adjuvant-radiotherapy-bart-acute-and-late-toxicity-from-a-phase-iii-multicenter 2024-09-29T23:27:19+00:00 weekly 0.7 https://trial.medpath.com/news/astro-2024-post-prostatectomy-linac-based-ultrahypofractionated-radiotherapy-for-urotoday 2024-09-29T23:27:16+00:00 weekly 0.7 https://trial.medpath.com/news/astro-2024-integrating-novel-therapeutics-with-trimodal-therapy-tmt-urotoday 2024-09-29T23:27:14+00:00 weekly 0.7 https://trial.medpath.com/news/astro-2024-the-space-time-continuum-in-metastatic-castration-sensitive-prostate-cancer 2024-09-29T23:27:13+00:00 weekly 0.7 https://trial.medpath.com/news/the-alarm-s-mike-peters-says-it-s-incredible-as-he-issues-huge-cancer-update-the-mirror 2024-09-29T23:12:15+00:00 weekly 0.7 https://trial.medpath.com/news/potential-of-device-assisted-therapy-for-advanced-stage-parkinson-disease-david-devos-md-phd 2024-09-29T23:03:30+00:00 weekly 0.7 https://trial.medpath.com/news/blockchain-technology-emerges-as-key-weapon-against-200b-counterfeit-drug-market 2024-09-29T23:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/people-who-experience-side-effects-from-cranial-radiation-therapy-may-recover-full 2024-09-29T21:18:23+00:00 weekly 0.7 https://trial.medpath.com/news/and-high-risk-localized-prostate-cancer-results-from-the-getug-14-randomized-phase-iii-trial 2024-09-29T21:15:57+00:00 weekly 0.7 https://trial.medpath.com/news/apac-clinical-services-market-set-to-reach-140-billion-by-2031-as-region-emerges-as-trial-powerhouse 2024-09-29T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pbt-imrt-provide-similar-patient-reported-outcomes-for-prostate-cancer-at-5-years 2024-09-29T19:16:45+00:00 weekly 0.7 https://trial.medpath.com/news/wall-street-swot-editas-medicine-stock-faces-challenges-in-competitive-gene-editing-market 2024-09-29T17:27:39+00:00 weekly 0.7 https://trial.medpath.com/news/radiopharmaceutical-therapy-offers-promise-for-people-with-tough-to-treat-meningioma-brain-tumors 2024-09-29T17:03:47+00:00 weekly 0.7 https://trial.medpath.com/news/bayer-submits-supplemental-new-drug-application-to-usfda-seeking-expanded-indication 2024-09-29T16:56:59+00:00 weekly 0.7 https://trial.medpath.com/news/not-a-placebo-study-finds-meditation-offers-genuine-pain-relief-sciencealert 2024-09-29T16:26:50+00:00 weekly 0.7 https://trial.medpath.com/news/first-interim-results-from-fine-real-a-prospective-non-interventional-phase-4-study 2024-09-29T15:15:34+00:00 weekly 0.7 https://trial.medpath.com/news/prior-local-therapy-does-not-impact-mcrpc-survival-with-arpi-treatment-urology-times 2024-09-29T14:40:52+00:00 weekly 0.7 https://trial.medpath.com/news/iaso-bio-presented-comparative-clinical-outcomes-on-the-optimal-lymphodepletion-prior 2024-09-29T14:26:47+00:00 weekly 0.7 https://trial.medpath.com/news/weekend-icymi-september-23-to-september-27-drug-topics 2024-09-29T14:24:42+00:00 weekly 0.7 https://trial.medpath.com/news/lumos-pharma-a-strong-buy-on-innovative-drug-prospects-and-solid-financials 2024-09-29T13:53:59+00:00 weekly 0.7 https://trial.medpath.com/news/avicenna-ai-receives-fda-510-k-clearance-for-cervical-spine-fracture-ai-tool-healio 2024-09-29T13:51:13+00:00 weekly 0.7 https://trial.medpath.com/news/alnylam-highlights-new-data-from-helios-b-study-of-vutrisiran-for-the-treatment-of-quantisnow 2024-09-29T13:18:13+00:00 weekly 0.7 https://trial.medpath.com/news/world-heart-day-2024-looking-back-at-cardiology-s-year-of-progress-in-cell-and-gene-therapy 2024-09-29T13:04:58+00:00 weekly 0.7 https://trial.medpath.com/news/study-protocol-for-early-tracking-of-childhood-health-determinants-etched 2024-09-29T12:24:15+00:00 weekly 0.7 https://trial.medpath.com/news/is-merck-stock-a-buy-the-globe-and-mail 2024-09-29T11:38:04+00:00 weekly 0.7 https://trial.medpath.com/news/858-therapeutics-drug-discovery-company-raises-50-million-series-b-pulse-2-0 2024-09-29T11:27:01+00:00 weekly 0.7 https://trial.medpath.com/news/effects-of-tenofovir-alafenamide-fumarate-on-serum-lipid-profiles-in-patients-with-chronic-hepatitis-b 2024-09-29T10:31:37+00:00 weekly 0.7 https://trial.medpath.com/news/2020-acr-guidelines-challenge-traditional-gout-management-in-chronic-kidney-disease-patients 2024-09-29T10:00:15+00:00 weekly 0.7 https://trial.medpath.com/news/discussing-interim-findings-on-nemolizumab-for-atopic-dermatitis-with-diamant-thaci-md 2024-09-29T08:02:02+00:00 weekly 0.7 https://trial.medpath.com/news/shingrix-vaccine-shows-strong-protection-against-shingles-in-ibd-patients-mayo-clinic-study-finds 2024-09-29T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/post-transplant-cyclophosphamide-breakthrough-expands-donor-pool-for-all-patients 2024-09-29T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/delavirdine-gains-approval-as-second-nnrti-for-anti-hiv-combination-regimens-pubmed 2024-09-29T05:45:18+00:00 weekly 0.7 https://trial.medpath.com/news/targeting-primary-tumor-metastasized-lesions-linked-to-improved-5-year-omhspc-survival 2024-09-29T05:24:16+00:00 weekly 0.7 https://trial.medpath.com/news/ga-68-psma-11-tracer-could-guide-scintix-radiation-therapy-for-metastasized-prostate-cancer 2024-09-29T04:43:58+00:00 weekly 0.7 https://trial.medpath.com/news/abos-acumen-pharmaceuticals-inc-latest-stock-news-market-updates 2024-09-29T03:16:56+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-outcomes-of-patients-treated-with-ribociclib-in-combination-w-itt 2024-09-29T02:25:03+00:00 weekly 0.7 https://trial.medpath.com/news/virologic-suppression-rate-and-associated-factors-for-third-line-hiv-treatment-in-addis-ababa 2024-09-29T00:37:58+00:00 weekly 0.7 https://trial.medpath.com/news/a-comparison-of-efficacy-of-erector-spinae-plane-block-versus-serratus-anterior-trials-journal 2024-09-28T23:37:50+00:00 weekly 0.7 https://trial.medpath.com/news/a-synuclein-antibody-lu-af82422-shows-disease-modifying-potential-in-phase-2-amulet 2024-09-28T22:56:04+00:00 weekly 0.7 https://trial.medpath.com/news/isatuximab-lenalidomide-demonstrates-strong-efficacy-tolerability-in-smoldering-multiple-myeloma 2024-09-28T22:10:16+00:00 weekly 0.7 https://trial.medpath.com/news/stress-confirmed-as-trigger-for-psoriasis-relapse-mcknight-s-long-term-care-news 2024-09-28T21:38:39+00:00 weekly 0.7 https://trial.medpath.com/news/the-role-of-endovascular-therapy-for-stroke-patients-mcknight-s-long-term-care-news 2024-09-28T21:35:40+00:00 weekly 0.7 https://trial.medpath.com/news/study-protocol-for-a-cluster-randomized-controlled-community-effectiveness-trial-of-the 2024-09-28T21:31:34+00:00 weekly 0.7 https://trial.medpath.com/news/bgne-beigene-ltd-american-depositary-shares-latest-stock-news-market-updates 2024-09-28T21:18:45+00:00 weekly 0.7 https://trial.medpath.com/news/nurses-talk-aes-interstitial-lung-disease-before-treating-with-t-dxd 2024-09-28T21:00:12+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-nvision-s-3d-printed-peek-interbody-system-voxelmatters 2024-09-28T20:02:32+00:00 weekly 0.7 https://trial.medpath.com/news/structural-basis-for-the-rescue-of-hyperexcitable-cells-by-the-amyotrophic-lateral-sclerosis 2024-09-28T19:58:01+00:00 weekly 0.7 https://trial.medpath.com/news/omeicos-therapeutics-completes-enrollment-in-phase-2a-pmd-option-study-of-omt-28-in 2024-09-28T19:30:22+00:00 weekly 0.7 https://trial.medpath.com/news/patient-reported-outcomes-similar-between-adalimumab-admb-reference-product-in 2024-09-28T17:07:06+00:00 weekly 0.7 https://trial.medpath.com/news/today-s-health-roundup-schizophrenia-breakthrough-and-bird-flu-vaccination-pressures 2024-09-28T16:58:08+00:00 weekly 0.7 https://trial.medpath.com/news/neurological-aes-not-significantly-affiliated-with-talquetamab-treatment-cancer-network 2024-09-28T16:55:50+00:00 weekly 0.7 https://trial.medpath.com/news/study-reveals-breakthrough-treatment-for-anxious-dogs-with-no-side-effects 2024-09-28T15:16:37+00:00 weekly 0.7 https://trial.medpath.com/news/th17-cells-may-serve-as-biomarker-in-metastatic-melanoma-targeted-oncology 2024-09-28T15:02:12+00:00 weekly 0.7 https://trial.medpath.com/news/intervention-to-reduce-sedentary-behavior-among-desk-workers-did-not-lower-blood-pressure 2024-09-28T14:38:09+00:00 weekly 0.7 https://trial.medpath.com/news/new-intervention-to-protect-lungs-during-cardiac-surgery-feasible-safe-and-effective-study-finds 2024-09-28T14:31:32+00:00 weekly 0.7 https://trial.medpath.com/news/study-finds-estrogens-play-a-hidden-role-in-cancers-inhibiting-a-key-immune-cell 2024-09-28T14:26:50+00:00 weekly 0.7 https://trial.medpath.com/news/zydus-gets-usfda-approval-to-produce-its-generic-prostate-cancer-drug-company-news 2024-09-28T14:17:59+00:00 weekly 0.7 https://trial.medpath.com/news/naveris-to-showcase-advances-in-precision-surveillance-for-hpv-associated-morningstar 2024-09-28T13:42:45+00:00 weekly 0.7 https://trial.medpath.com/news/enliven-therapeutics-announces-positive-data-update-from-phase-1-clinical-trial-of-elvn 2024-09-28T13:40:42+00:00 weekly 0.7 https://trial.medpath.com/news/taiwan-s-anbogen-inks-deal-with-beigene-to-evaluate-combination-therapy-in-colorectal-cancer 2024-09-28T13:06:30+00:00 weekly 0.7 https://trial.medpath.com/news/dea-calls-to-increase-production-of-psychedelics-for-clinical-research-lucid-news 2024-09-28T12:28:53+00:00 weekly 0.7 https://trial.medpath.com/news/new-clinical-data-demonstrate-excellent-lesion-durability-with-pulseselecttm-pulsed-field 2024-09-28T11:00:47+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-ge-healthcare-s-flurpiridaz-f-18-pet-radiotracer-for-cad 2024-09-28T10:10:43+00:00 weekly 0.7 https://trial.medpath.com/news/enanta-s-phase-ii-challenge-data-position-a-second-potential-rsv-therapy-scrip 2024-09-28T09:39:36+00:00 weekly 0.7 https://trial.medpath.com/news/hypofractionated-radiation-therapy-improves-10-year-prostate-cancer-outcomes 2024-09-28T09:23:36+00:00 weekly 0.7 https://trial.medpath.com/news/the-weekly-roundup-september-23-27-dermatology-times 2024-09-28T09:07:20+00:00 weekly 0.7 https://trial.medpath.com/news/why-glp-1s-might-treat-a-plethora-of-conditions-becker-s-hospital-review 2024-09-28T08:34:30+00:00 weekly 0.7 https://trial.medpath.com/news/carvykti-r-is-the-first-and-only-cell-therapy-to-significantly-extend-overall-survival-versus 2024-09-28T08:30:34+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-cepheus-phase-3-study-shows-improvement-for-patients-with-multiple 2024-09-28T07:43:50+00:00 weekly 0.7 https://trial.medpath.com/news/deuruxolitinib-shows-efficacy-in-hair-regrowth-patient-satisfaction-and-psychosocial 2024-09-28T07:22:07+00:00 weekly 0.7 https://trial.medpath.com/news/novel-antibody-drug-conjugate-hdp-101-shows-promise-in-relapsed-multiple-myeloma 2024-09-28T07:01:37+00:00 weekly 0.7 https://trial.medpath.com/news/radiation-therapy-the-immune-system-and-what-s-ahead-md-anderson-cancer-center 2024-09-28T07:00:34+00:00 weekly 0.7 https://trial.medpath.com/news/glucocorticoid-receptor-targeting-with-relacorilant-may-improve-ovarian-cancer-outcomes 2024-09-28T06:34:54+00:00 weekly 0.7 https://trial.medpath.com/news/study-reveals-heightened-depression-risk-in-retinitis-pigmentosa-patients-particularly-among-young-adults 2024-09-28T06:21:00+00:00 weekly 0.7 https://trial.medpath.com/news/pop-biotechnologies-announces-phase-3-trial-interim-results-published-for-covid-19 2024-09-28T06:09:54+00:00 weekly 0.7 https://trial.medpath.com/news/ultra-processed-foods-linked-to-17-higher-type-2-diabetes-risk-in-large-european-study 2024-09-28T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/zelenectide-pevedotin-shows-early-promise-as-less-toxic-alternative-to-standard 2024-09-28T05:06:12+00:00 weekly 0.7 https://trial.medpath.com/news/commonly-used-drug-could-transform-treatment-of-rare-muscle-disorder-medical-xpress 2024-09-28T05:04:29+00:00 weekly 0.7 https://trial.medpath.com/news/olomorasib-combo-elicits-favorable-efficacy-in-nsclc-targeted-oncology 2024-09-28T05:01:44+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-submits-biologics-license-application-to-the-fda-for-telisotuzumab-vedotin-teliso 2024-09-28T04:17:25+00:00 weekly 0.7 https://trial.medpath.com/news/dietary-factors-show-protective-effects-against-iga-nephropathy-in-landmark-mendelian-study 2024-09-28T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/vitamin-d-for-the-management-of-chronic-obstructive-pulmonary-disease-pubmed 2024-09-28T02:43:51+00:00 weekly 0.7 https://trial.medpath.com/news/dr-victoria-kunene-on-personalised-colorectal-cancer-vaccines-for-prevention-and-therapy 2024-09-28T02:03:51+00:00 weekly 0.7 https://trial.medpath.com/news/here-s-the-article-based-on-the-provided-information-by-investing-com 2024-09-28T01:48:40+00:00 weekly 0.7 https://trial.medpath.com/news/effectiveness-of-the-dyadic-coping-intervention-of-social-participation-dcisp-for-stroke-survivors 2024-09-28T01:39:20+00:00 weekly 0.7 https://trial.medpath.com/news/wall-street-swot-aquestive-therapeutics-stock-poised-for-potential-breakthrough 2024-09-28T00:49:17+00:00 weekly 0.7 https://trial.medpath.com/news/cepheus-outcomes-support-daratumumab-plus-vrd-as-soc-in-multiple-myeloma 2024-09-28T00:06:45+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-ind-clearance-for-minovia-s-phase-ib-mds-therapy-trial 2024-09-27T23:08:19+00:00 weekly 0.7 https://trial.medpath.com/news/dr-gluz-on-survival-outcomes-with-de-escalated-neoadjuvant-regimens-in-hr-her2 2024-09-27T22:53:04+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-s-parkinson-s-drug-tavapadon-a-market-perform-rating-amidst-competitive 2024-09-27T22:24:30+00:00 weekly 0.7 https://trial.medpath.com/news/late-breaking-data-at-eadv-of-esk-001-an-oral-tyk2-inhibitor-for-the-treatment-of-biospace 2024-09-27T22:02:52+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-expanded-indication-for-linear-health-sciences-orchid-safety-release-valve 2024-09-27T20:42:13+00:00 weekly 0.7 https://trial.medpath.com/news/has-albrecht-been-undone-insights-holland-knight 2024-09-27T20:37:39+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-selpercatinib-for-ret-fusion-medullary-thyroid-cancer 2024-09-27T19:37:47+00:00 weekly 0.7 https://trial.medpath.com/news/boston-scientific-wins-farapulse-pfa-approval-in-japan-massdevice 2024-09-27T19:37:41+00:00 weekly 0.7 https://trial.medpath.com/news/cereno-scientific-announces-positive-topline-results-of-phase-iia-trial-with-lead-candidate 2024-09-27T18:42:30+00:00 weekly 0.7 https://trial.medpath.com/news/neurona-therapeutics-announces-participation-in-upcoming-investor-conferences-in-october 2024-09-27T18:10:49+00:00 weekly 0.7 https://trial.medpath.com/news/lexicon-to-present-phase-3-trial-design-for-sotagliflozin-globenewswire 2024-09-27T18:10:16+00:00 weekly 0.7 https://trial.medpath.com/news/grand-rounds-october-18-2024-rigorous-testing-of-behavior-change-interventions 2024-09-27T18:07:10+00:00 weekly 0.7 https://trial.medpath.com/news/staggering-breast-cancer-breakthrough-as-drug-trial-drastically-shrinks-tumours-by-65-uk 2024-09-27T18:00:30+00:00 weekly 0.7 https://trial.medpath.com/news/antibody-drug-conjugates-and-immune-checkpoint-inhibitors-in-cancer-treatment-nature 2024-09-27T17:28:28+00:00 weekly 0.7 https://trial.medpath.com/news/wall-street-swot-atyr-pharma-stock-rides-wave-of-clinical-progress-amid-risks 2024-09-27T17:14:56+00:00 weekly 0.7 https://trial.medpath.com/news/galectin-9-as-a-new-biomarker-of-acute-on-chronic-liver-failure-scientific-reports-nature 2024-09-27T16:25:30+00:00 weekly 0.7 https://trial.medpath.com/news/biosimilars-generate-12-3-billion-in-healthcare-savings-for-2023-yet-market-challenges-persist 2024-09-27T16:00:32+00:00 weekly 0.7 https://trial.medpath.com/news/pas-004-has-tolerable-safety-profile-and-preliminary-efficacy-in-mapk-driven-solid-tumors 2024-09-27T15:59:49+00:00 weekly 0.7 https://trial.medpath.com/news/in-first-type-1-diabetic-cured-by-allogeneic-stem-cell-transplant 2024-09-27T15:42:35+00:00 weekly 0.7 https://trial.medpath.com/news/nyu-langone-health-in-the-news-friday-september-27-2024 2024-09-27T15:26:39+00:00 weekly 0.7 https://trial.medpath.com/news/lundbeck-presents-results-from-two-studies-in-multiple-system-atrophy-at-international 2024-09-27T15:20:28+00:00 weekly 0.7 https://trial.medpath.com/news/rezolute-stock-holds-steady-with-buy-rating-from-hc-wainwright-investing-com 2024-09-27T15:13:07+00:00 weekly 0.7 https://trial.medpath.com/news/key-considerations-for-digital-decentralised-clinical-trials-from-a-feasibility-study-assessing 2024-09-27T15:10:30+00:00 weekly 0.7 https://trial.medpath.com/news/non-clinical-evaluation-of-pmil12-gene-therapy-for-approval-of-the-phase-i-clinical-study 2024-09-27T15:08:45+00:00 weekly 0.7 https://trial.medpath.com/news/j-j-builds-case-for-talvey-fda-panel-questions-pd-1-drugs-for-certain-cancers 2024-09-27T14:58:06+00:00 weekly 0.7 https://trial.medpath.com/news/the-data-are-clear-patients-regain-weight-after-stopping-glp-1-drugs-medpage-today 2024-09-27T14:46:46+00:00 weekly 0.7 https://trial.medpath.com/news/practical-lessons-and-insights-from-seasoned-drug-hunters 2024-09-27T14:19:46+00:00 weekly 0.7 https://trial.medpath.com/news/bristol-myers-squibb-shares-move-higher-on-fda-approval-of-schizophrenia-drug 2024-09-27T13:41:01+00:00 weekly 0.7 https://trial.medpath.com/news/leo-pharma-files-for-approval-of-psoriasis-treatment-enstilar-in-china-medwatch 2024-09-27T13:33:49+00:00 weekly 0.7 https://trial.medpath.com/news/nccn-guidelines-update-evolving-treatment-landscape-for-graft-vs-host-disease-management 2024-09-27T13:00:54+00:00 weekly 0.7 https://trial.medpath.com/news/a-bayesian-multivariate-hierarchical-model-for-developing-a-treatment-benefit-index-using 2024-09-27T12:51:47+00:00 weekly 0.7 https://trial.medpath.com/news/septerna-announces-initiation-of-phase-1-clinical-trial-with-sep-786-a-novel-oral-small 2024-09-27T12:47:32+00:00 weekly 0.7 https://trial.medpath.com/news/bayer-s-bemdaneprocel-for-parkinson-s-disease-shows-positive-data-at-24-months 2024-09-27T12:33:29+00:00 weekly 0.7 https://trial.medpath.com/news/savara-announces-expanded-access-program-eap-for-molgramostim-inhalation-solution 2024-09-27T12:16:32+00:00 weekly 0.7 https://trial.medpath.com/news/pfizer-jefferies-lowers-price-target-marketscreener 2024-09-27T12:16:10+00:00 weekly 0.7 https://trial.medpath.com/news/cardurion-pharmaceuticals-selected-as-an-endpoints-11-most-promising-biotech-company 2024-09-27T12:12:38+00:00 weekly 0.7 https://trial.medpath.com/news/impact-biotech-announces-50-enrollment-in-phase-3-enlighted-clinical-trial-of 2024-09-27T12:08:56+00:00 weekly 0.7 https://trial.medpath.com/news/real-world-performance-analysis-of-gprc5d-bispecific-therapies-in-relapsed-multiple-myeloma 2024-09-27T11:50:55+00:00 weekly 0.7 https://trial.medpath.com/news/mhra-approves-first-medicine-for-rare-immune-disease-apds-gov-uk 2024-09-27T11:37:56+00:00 weekly 0.7 https://trial.medpath.com/news/reporting-and-communication-of-sample-size-calculations-in-adaptive-clinical-trials 2024-09-27T11:37:42+00:00 weekly 0.7 https://trial.medpath.com/news/stem-cells-reverse-woman-s-diabetes-a-world-first-healthleaders-media 2024-09-27T11:25:43+00:00 weekly 0.7 https://trial.medpath.com/news/press-release-dupixent-approved-in-china-as-the-first-ever-biologic-medicine-for-patients 2024-09-27T11:14:20+00:00 weekly 0.7 https://trial.medpath.com/news/poltreg-begins-car-treg-development-for-neuroinflammatory-disease 2024-09-27T11:05:48+00:00 weekly 0.7 https://trial.medpath.com/news/occlusive-retinal-vasculitis-associated-with-intravitreal-faricimab-injections 2024-09-27T10:41:22+00:00 weekly 0.7 https://trial.medpath.com/news/alembic-pharma-secures-fda-approval-for-schizophrenia-treatment-stocks-in-red 2024-09-27T10:26:29+00:00 weekly 0.7 https://trial.medpath.com/news/ose-immunotherapeutics-announces-historic-h1-2024-results-and-provides-corporate-update 2024-09-27T09:45:47+00:00 weekly 0.7 https://trial.medpath.com/news/a-multi-center-double-blind-placebo-controlled-randomized-parallel-group-non-inferiority 2024-09-27T09:39:56+00:00 weekly 0.7 https://trial.medpath.com/news/trial-of-pathogen-reduced-cryoprecipitate-vs-cryoprecipitated-ahf-to-lower-operative 2024-09-27T09:39:56+00:00 weekly 0.7 https://trial.medpath.com/news/upping-dose-of-anti-opioid-drug-might-work-better-to-curb-addiction 2024-09-27T09:09:37+00:00 weekly 0.7 https://trial.medpath.com/news/viral-infections-emerge-as-critical-consideration-in-rheumatic-disease-management 2024-09-27T08:42:53+00:00 weekly 0.7 https://trial.medpath.com/news/dispute-over-duchenne-gene-therapy-highlights-thorny-access-issues-stat-news 2024-09-27T08:35:38+00:00 weekly 0.7 https://trial.medpath.com/news/urteste-expands-development-of-innovative-diagnostic-projects-biospace 2024-09-27T08:07:46+00:00 weekly 0.7 https://trial.medpath.com/news/genprex-makes-moves-to-bring-its-gene-therapy-product-reqorsa-to-mesothelioma 2024-09-27T08:02:35+00:00 weekly 0.7 https://trial.medpath.com/news/formycon-and-fresenius-kabi-receive-european-commission-approval-for-fyb202-otulfi 2024-09-27T07:24:52+00:00 weekly 0.7 https://trial.medpath.com/news/xbrane-provides-update-from-scientific-advice-with-us-fda-on-xdivanetm-opdivo 2024-09-27T07:04:17+00:00 weekly 0.7 https://trial.medpath.com/news/psma-targeted-radiopharmaceuticals-transform-advanced-prostate-cancer-treatment-landscape 2024-09-27T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/shionogi-submits-new-drug-application-in-japan-for-zuranolone-as-a-treatment-for-major 2024-09-27T02:35:10+00:00 weekly 0.7 https://trial.medpath.com/news/pilot-study-of-il-1-antagonist-anakinra-for-treatment-of-endometriosis-dove-medical-press 2024-09-27T02:27:10+00:00 weekly 0.7 https://trial.medpath.com/news/travere-therapeutics-announces-voluntary-pause-of-enrollment-in-the-phase-3-harmony 2024-09-27T02:13:08+00:00 weekly 0.7 https://trial.medpath.com/news/arpa-h-awards-27m-to-phare-bio-for-ai-powered-antibiotic-discovery-platform 2024-09-27T02:12:39+00:00 weekly 0.7 https://trial.medpath.com/news/union-plans-phase-iii-trial-for-atopic-dermatitis-after-phase-iib-win-clinical-trials-arena 2024-09-27T01:25:36+00:00 weekly 0.7 https://trial.medpath.com/news/biocon-partners-with-tabuk-to-launch-glp-1-therapies-across-middle-east-markets 2024-09-27T00:16:42+00:00 weekly 0.7 https://trial.medpath.com/news/surufatinib-plus-toripalimab-combined-with-etoposide-and-cisplatin-as-first-line-treatment-in-nature 2024-09-27T00:10:29+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-submits-biologics-license-application-to-the-fda-for-telisotuzumab-vedotin-teliso-v-in-previously-treated-non-small-cell-lung-cancer 2024-09-27T00:09:06+00:00 weekly 0.7 https://trial.medpath.com/news/canadian-real-world-study-finds-no-increased-infection-risk-with-tnf-inhibitor-biosimilars 2024-09-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/new-published-data-show-reproducibility-and-utility-of-perspectum-s-mri-in-patients-with 2024-09-26T23:33:17+00:00 weekly 0.7 https://trial.medpath.com/news/cassava-sciences-shares-fall-after-sec-charges-for-misleading-alzheimer-s-drug-trial-claims 2024-09-26T23:08:55+00:00 weekly 0.7 https://trial.medpath.com/news/bristol-myers-squibb-and-2seventy-bio-halt-karmma-9-trial-in-patients-with-newly 2024-09-26T21:11:45+00:00 weekly 0.7 https://trial.medpath.com/news/establishment-labs-receives-u-s-fda-approval-for-motiva-implants-yahoo-finance 2024-09-26T21:09:43+00:00 weekly 0.7 https://trial.medpath.com/news/intrapatient-intermetastatic-heterogeneity-determined-by-triple-tracer-pet-imaging-in 2024-09-26T20:47:15+00:00 weekly 0.7 https://trial.medpath.com/news/vivani-can-begin-first-in-human-glp-1-implant-trial-in-australia-drug-delivery-business 2024-09-26T19:59:55+00:00 weekly 0.7 https://trial.medpath.com/news/belantamab-combo-shows-promising-outcomes-in-transplant-eligible-ndmm 2024-09-26T19:49:41+00:00 weekly 0.7 https://trial.medpath.com/news/orion-s-collaboration-partner-bayer-submits-application-to-u-s-fda-for-third-indication-of 2024-09-26T19:33:57+00:00 weekly 0.7 https://trial.medpath.com/news/enanta-pharmaceuticals-announces-positive-topline-results-for-edp-323-in-a-phase-biospace 2024-09-26T19:33:34+00:00 weekly 0.7 https://trial.medpath.com/news/cyclacel-pharmaceuticals-announces-completion-of-enrollment-in-the-biomarker-enriched 2024-09-26T19:33:34+00:00 weekly 0.7 https://trial.medpath.com/news/israeli-device-is-new-drug-free-solution-for-men-coping-with-ed-nocamels 2024-09-26T19:28:11+00:00 weekly 0.7 https://trial.medpath.com/news/placebos-linked-to-potential-harms-in-ibd-clinical-trials-medpage-today 2024-09-26T19:00:50+00:00 weekly 0.7 https://trial.medpath.com/news/genentech-s-gazyva-hits-primary-endpoint-in-late-stage-kidney-disease-trial 2024-09-26T18:42:57+00:00 weekly 0.7 https://trial.medpath.com/news/fda-lifts-clinical-hold-on-bmf-219-in-type-2-and-type-1-diabetes-trials-morningstar 2024-09-26T18:35:33+00:00 weekly 0.7 https://trial.medpath.com/news/based-on-hope-and-love-ub-celebrates-opening-of-foxg1-research-center-ubnow 2024-09-26T18:02:51+00:00 weekly 0.7 https://trial.medpath.com/news/thrombolytic-science-receives-fda-investigational-new-drug-clearance 2024-09-26T18:02:08+00:00 weekly 0.7 https://trial.medpath.com/news/journalists-question-safety-and-effectiveness-of-new-alzheimer-s-drug 2024-09-26T17:49:27+00:00 weekly 0.7 https://trial.medpath.com/news/patient-friendly-news-you-can-use-september-creakyjoints 2024-09-26T17:35:34+00:00 weekly 0.7 https://trial.medpath.com/news/eye-on-pharma-ec-approved-ustekinumab-zymfentra-expansion-biosimilar-policy-briefing 2024-09-26T17:26:39+00:00 weekly 0.7 https://trial.medpath.com/news/eyenovia-announces-launch-and-commercial-availability-of-clobetasol-propionate-quantisnow 2024-09-26T17:21:56+00:00 weekly 0.7 https://trial.medpath.com/news/polarcool-takes-an-important-step-towards-launching-in-the-us-cision-news 2024-09-26T16:50:56+00:00 weekly 0.7 https://trial.medpath.com/news/biomedical-research-improvements-needed-to-the-quality-of-information-about-dod-and 2024-09-26T16:49:04+00:00 weekly 0.7 https://trial.medpath.com/news/her2-and-lung-cancer-new-test-holds-great-promise-to-help-far-more-patients 2024-09-26T16:36:53+00:00 weekly 0.7 https://trial.medpath.com/news/intrathecal-pain-pump-improves-pancreatic-cancer-patient-s-life 2024-09-26T16:36:16+00:00 weekly 0.7 https://trial.medpath.com/news/new-self-swab-hpv-test-is-an-alternative-to-pap-smears-here-s-how-it-works-live-science 2024-09-26T16:30:06+00:00 weekly 0.7 https://trial.medpath.com/news/axonics-wins-regulatory-nod-in-australia-for-latest-sacral-neuromod-system-massdevice 2024-09-26T16:01:47+00:00 weekly 0.7 https://trial.medpath.com/news/moderna-blamed-after-children-offered-ps1500-to-take-part-in-covid-19-trial 2024-09-26T15:58:40+00:00 weekly 0.7 https://trial.medpath.com/news/nih-plots-path-forward-for-clinical-trials-of-long-covid-treatments-c-en 2024-09-26T15:50:34+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-announces-positive-topline-results-from-phase-3-tempo-1-trial-evaluating 2024-09-26T15:38:07+00:00 weekly 0.7 https://trial.medpath.com/news/pfizer-withdraws-scd-drug-oxbryta-after-ema-discloses-16-deaths-in-trials 2024-09-26T15:37:35+00:00 weekly 0.7 https://trial.medpath.com/news/fda-proposes-reclassifying-hepatitis-b-assays-medtech-dive 2024-09-26T15:20:15+00:00 weekly 0.7 https://trial.medpath.com/news/press-releases-wednesday-sep-25-2024-genentech 2024-09-26T15:11:30+00:00 weekly 0.7 https://trial.medpath.com/news/immunai-astrazeneca-collaborate-to-optimize-cancer-clinical-trials-the-jerusalem-post 2024-09-26T15:10:45+00:00 weekly 0.7 https://trial.medpath.com/news/kidney-cancer-questions-answered-from-protein-intake-to-clinical-trials-cure-today 2024-09-26T15:05:31+00:00 weekly 0.7 https://trial.medpath.com/news/breast-cancer-drugs-fda-approval-development-time-efficacy-clinical-benefits-innovation 2024-09-26T14:43:58+00:00 weekly 0.7 https://trial.medpath.com/news/phase-3-lunar-trial-dr-rolfo-discusses-new-analysis-at-iaslc-2024-world-conference 2024-09-26T14:43:12+00:00 weekly 0.7 https://trial.medpath.com/news/govt-drafts-sop-to-regulate-clinical-research-organizations-mint 2024-09-26T14:40:16+00:00 weekly 0.7 https://trial.medpath.com/news/alzheimer-s-breakthrough-as-wonder-drug-approved-but-might-not-be-available-in-the-uk 2024-09-26T14:14:01+00:00 weekly 0.7 https://trial.medpath.com/news/rx-road-map-glofitamab-gxbm-columvi-oncology-nursing-news 2024-09-26T14:10:04+00:00 weekly 0.7 https://trial.medpath.com/news/eadv-2024-wegovy-shows-promise-in-treating-common-chronic-skin-condition 2024-09-26T13:42:45+00:00 weekly 0.7 https://trial.medpath.com/news/a-first-in-human-study-of-cinrebafusp-alfa-a-her2-4-1bb-bispecific-molecule-in-patients 2024-09-26T13:28:32+00:00 weekly 0.7 https://trial.medpath.com/news/acasti-pharma-shares-maintain-buy-rating-from-hc-wainwright-investing-com 2024-09-26T13:26:39+00:00 weekly 0.7 https://trial.medpath.com/news/longeveron-to-attend-alliance-for-regenerative-medicine-s-cell-gene-meeting-on-the-mesa 2024-09-26T13:11:27+00:00 weekly 0.7 https://trial.medpath.com/news/metabolic-reprogramming-of-t-cells-may-enhance-checkpoint-inhibitor-therapy-newsroom 2024-09-26T13:10:23+00:00 weekly 0.7 https://trial.medpath.com/news/mural-oncology-s-first-virtual-investor-day-to-highlight-late-stage-clinical-progress 2024-09-26T12:59:00+00:00 weekly 0.7 https://trial.medpath.com/news/cervomed-to-deliver-late-breaking-oral-presentations-at-the-17th-clinical-trials-on 2024-09-26T12:32:21+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-ptc518-huntington-s-disease-program-stock-titan 2024-09-26T12:17:27+00:00 weekly 0.7 https://trial.medpath.com/news/projenx-and-unlearn-announce-partnership-to-augment-als-clinical-trial-pro-101-with 2024-09-26T12:00:29+00:00 weekly 0.7 https://trial.medpath.com/news/vertex-highlights-first-oral-presentation-of-phase-3-clinical-data-of-the-vanza-triple-and 2024-09-26T11:34:32+00:00 weekly 0.7 https://trial.medpath.com/news/dong-a-st-s-ecg-monitoring-platform-hicardi-h100-receives-u-s-fda-approval 2024-09-26T11:13:04+00:00 weekly 0.7 https://trial.medpath.com/news/ani-pharmaceuticals-announces-fda-approval-launch-of-ketoconazole-shampoo-2 2024-09-26T10:57:11+00:00 weekly 0.7 https://trial.medpath.com/news/hamlet-biopharma-reports-positive-results-from-phase-ii-study-in-acute-cystitis 2024-09-26T10:38:10+00:00 weekly 0.7 https://trial.medpath.com/news/novel-monoclonal-antibody-shows-promise-in-ulcerative-colitis-medpage-today 2024-09-26T10:35:13+00:00 weekly 0.7 https://trial.medpath.com/news/during-ny-climate-week-alex-zhavoronkov-phd-eurekalert 2024-09-26T10:21:53+00:00 weekly 0.7 https://trial.medpath.com/news/innovent-announces-nmpa-acceptance-of-nda-for-picankibart-anti-il-23p19-antibody-for 2024-09-26T10:15:54+00:00 weekly 0.7